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Background: Adequate micronutrient status plays a key role in preventing or 
delaying the progression of age-related diseases. However, the physiological and 
psychosocial changes associated with ageing increase the risk of nutritional 
deficiencies. Few studies have investigated the micronutrient status of older adults in 
New Zealand. In particular, a number of B-vitamins may be at increased risk of 
suboptimal status leading to an increase in homocysteine concentrations – a key 
intermediate of one-carbon metabolism commonly associated with age-related diseases. 
Objectives: The aim of the study was to determine the status of folate, riboflavin, 
vitamin B6 and vitamin B12, and the prevalence of hyperhomocysteinemia in older 
New Zealand adults living in residential aged care facilities (RACF). Furthermore, the 
relationship between homocysteine and B-vitamin status (including betaine and 
choline), along with existing conditions of depression, diabetes and stroke were 
investigated. 
Design and method: In this cross-sectional study, blood samples were 
collected from 263 older adults (> 65 years) living in 16 RACF across New Zealand. 
Detailed medical history, including medication use and anthropometric measurements 
were collected. The Geriatric Depression Scale-Short Form (GDS-SF) and Mini 
Nutritional Assessment-Short Form were used to screen for depression and 
malnutrition, respectively; and the Survey of Health, Ageing and Retirement in Europe 
Frailty Instrument (SHARE-FI) was used to score frailty. Fasting blood samples were 
analysed for serum folate, serum vitamin B12, riboflavin and vitamin B6, as well as 
plasma homocysteine, betaine and choline. Inflammatory markers [C-reactive protein 
(CRP),  alpha-1-acid glycoprotein (AGP) and interleukin-6 (IL-6)] were also measured.  
Results: The mean age of participants was 85 years; the majority were women and 
of New Zealand European descent. The average length of RACF stay was 32 months. 
Fewer than 10% of participants were malnourished, 7% were underweight and 52% 
were classified as frail. More than half of the sample population had hypertension, 25%  
had diabetes, 24% had a history of a cerebrovascular accident (CVA) or transient 
ischemic attack (TIA), and 30% were classified as being depressed (GDS-SF > 5). 
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Vitamin B6 (EAST-AC > 1.85) had the highest prevalence of deficiency (36.5%) 
among participants followed by serum folate 8.9% (< 6.8 nmol/L) and vitamin B12 
0.4% (< 148 pmol/L). Riboflavin deficiency (EGR-AC > 1.4) was not present among 
our sample population. Nonetheless, marginal status of vitamin B12 (148-221 pmol/L) 
and riboflavin (EGR-AC 1.2-1.4) existed in 7.6% and 4.1%, respectively. Over two-
thirds of participants exhibited elevated homocysteine (> 15 mol/L). Multiple linear 
regression showed that homocysteine was negatively associated with folate, vitamin 
B12, and betaine (p < 0.001), and positively associated with choline (p < 0.001), 
controlling for renal function (estimated glomerular filtration rate), inflammation (IL-6) 
and diuretic use. No association was found between homocysteine and diabetes, stroke 
and depression. 
Conclusions: In older adults living in RACF in New Zealand, the prevalence of 
folate, vitamin B12 and riboflavin deficiency was low, while vitamin B6 deficiency 
was high. Further work is needed to confirm our findings, in particular vitamin B6 due 
to the known assay limitations. Given the high prevalence of hyperhomocysteinemia 
and its negative association with folate and vitamin B12, it is unknown whether an 
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1. Introduction and objectives  
Globally, the population aged 65 years and over is growing rapidly, with nearly 
one in five people projected to reach this age group by 2050 (He, Goodkind, & Kowal, 
2016). In New Zealand (NZ), it is estimated that the number of older adults will 
account for more than a quarter of the total population by 2068 (Statistics New Zealand 
Tatauranga Aotearoa, 2016).  
Living longer, however, does not mean living independently nor in good health. 
Poor nutritional status in older adults is a major concern leading to an increased risk of 
malnutrition and frailty (Clegg, Young, Iliffe, Rikkert, & Rockwood, 2013; Fávaro-
Moreira et al., 2016). Those who live in residential aged care facilities (RACF) exhibit 
the highest risk of malnutrition (up to 39%) compared to community-dwelling older 
adults (< 5%) (Cereda et al., 2016; Verbrugghe et al., 2013; Wham et al., 2017). 
Malnutrition in older adults may arise due to changes in physiology (absorption 
and utilisation of nutrients, poor appetite, loss of smell and taste), the presence of 
chronic diseases, the use of medications and changing psychosocial factors (Hickson, 
2006). Although the focus of malnutrition among the ageing population is often on 
protein-energy undernutrition (Visser et al., 2017), multiple micronutrient deficiencies 
are frequently present and play an important role in preventing or delaying the 
progression of age-related diseases (Leslie & Hankey, 2015). In particular, 
degenerative diseases, including cardiovascular disease, cognitive impairment, 
osteoporosis and diabetes have been associated with low B-vitamin status, and/or 
elevated concentrations of homocysteine via the complex pathway of one-carbon 
metabolism (Mursleen & Riaz, 2017; Porter et al., 2016). To date, studies investigating 
the role of B-vitamins in health and disease in the ageing population have focused 
predominantly on folate and/or vitamin B12 rather than a wider investigation of other 
potentially co-existing metabolically linked micronutrient deficiencies, such as vitamin 
B6 and riboflavin. Moreover, data on the biochemical status of folate, vitamin B12, 
riboflavin, vitamin B6 and homocysteine levels in older adults in RACF are limited 
globally and no data are available in New Zealand. 
A better understanding of the risk of multiple B-vitamin deficiencies among 
older adults, particularly among the growing population of aged-cared residents, will 
serve to further explore the role of these nutrients in preventing or delaying diseases of 
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ageing. To this end, the present thesis focusses on the biochemical status of folate, 
vitamin B12, riboflavin and vitamin B6 in older adults in RACF in New Zealand. In 
addition, given the multiple micronutrient biochemical assessment of the sample 
population, both nutritional and non-nutritional predictors of homocysteine, and the 
association of such with depression, diabetes and stroke in this population was also 
investigated. 
 
The specific study objectives were:  
1. To describe select one carbon nutrient status and determine the prevalence of 
folate, vitamin B12, vitamin B6 and riboflavin deficiencies among older adults 
in residential aged-care facilities in New Zealand. 
2. To determine the prevalence of hyperhomocysteinemia and explore the 
predictors of homocysteine in this population. 
3. To investigate the association between homocysteine and health conditions such 
as diabetes, stroke and depression. 
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2. Literature Review 
Worldwide, 125 million people were 80 years of age or older in 2015, a number 
estimated to increase substantially to 434 million by 2050 (World Health Organisation, 
2018a). Ageing results in a decline of mental and physical functioning and an increased 
risk of chronic diseases, making living independently challenging (Clouston et al., 
2013). Many countries have “ageing in place” policies to support older adults to live in 
their own homes as long as possible, resulting in the average age of admission to RACF 
increasing in New Zealand to 84 years (Thornton, 2010). Nevertheless, the demand for 
RACF is expected to increase in the future due to the expected growth in this 
demographic (Ernst & Young, 2019). For example, in 2013, 31,899 people resided in 
RACF in New Zealand, reflecting a 14% increase since 2006 (Statistics New Zealand 
Tatauranga Aotearoa, 2015). Furthermore, a recent Aged Residential Care Service 
Review estimated that 52,000 beds will be needed in RACF in NZ by 2026 (Thornton, 
2010). 
The risk, and prevalence of malnutrition among residential care older adults is 
high (Borgström Bolmsjö, Jakobsson, Mölstad, Östgren, & Midlöv, 2015; Chan, Lim, 
Ernest, & Tan, 2010; Gaskill et al., 2008; Törmä, Winblad, Cederholm, & Saletti, 2013; 
Wham et al., 2017). Malnutrition can lead to micronutrient deficiencies including 
folate, vitamin B12, riboflavin and vitamin B6 deficiencies (Jyvakorpi et al., 2015; 
Kjeldby, Fosnes, Ligaarden, & Farup, 2013; Sahin et al., 2016). Potential causes of B-
vitamin deficiency in older adults include inadequate intake, increased requirements, 
drug-nutrient interactions, alcohol abuse and malabsorption (Porter et al., 2016). The 
consequences of low B-vitamin status in the development of chronic diseases of ageing 
such as cardiovascular disease, cognitive impairment, osteoporosis, cancer, depression 
and diabetes, are a growing area of research interest. Suboptimal nutritional status is a 
modifiable risk factor and preventing or delaying the onset of these diseases by means 
of ensuring adequate nutritional status should be a public health priority.  
This literature review will examine the commonly used direct and indirect 
functional biomarkers to determine folate, vitamin B12, vitamin B6 and riboflavin; 
review the evidence to date of low B-vitamin status in older people; and, examine the 
evidence linking homocysteine and related one-carbon metabolites with health and age-
related disease outcomes.  
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2.1 Folate 
Folate is a generic name for a group of structurally related compounds, 
including the synthetic form of folic acid found in supplements and fortified food 
(Gibson, 2005a). Natural food folate is found in green leafy vegetables (salad greens, 
spinach, kale), broccoli, brussels sprouts, asparagus, nuts and seeds, legumes, eggs, 
liver, citrus fruit, banana and avocado (The New Zealand Institute for Plant and Food 
Research & Ministry of Health, 2019). Some countries such as the USA, Canada, Chile 
and Australia have mandatory folic acid fortification of flour (Hoddinott, 2018) 
whereby folate is widespread in the food supply. New Zealand along with several 
European countries allow only voluntary folic acid fortification of some foods such as 
breads, breakfast cereals and fruit juices (Ministry of Health, 2019a). 
2.1.1 Biomarkers of folate status and deficiency  
Body stores of folate typically represent a two to three-month supply in a 
healthy adult (Gibson, 2005a). Folate deficiency can occur due to suboptimal intakes, 
impaired absorption or increased requirement for the vitamin (Hausman et al., 2015). 
The clinical presentation of folate deficiency progresses as follows: decline in serum 
folate concentration followed by an increase in homocysteine and a reduction in red 
blood cell folate. Megaloblastic changes also appear in the bone marrow and other 
rapidly dividing tissues, leading to macrocytic anaemia and hypersegmentation of 
nuclei in neutrophils (Hausman et al., 2015). Symptoms of folate deficiency are non-
specific and include weakness, fatigue, irritability and shortness of breath (Gibson, 
2005a).  
The two main biochemical indicators of folate status are serum or plasma and 
red blood cell folate (Hausman et al., 2015). Plasma or serum homocysteine, a 
functional test of folate deficiency, is a sensitive biomarker of folate status and 
increases with poor folate status; however, homocysteine is not a specific marker of 
folate status as it is also altered due to declines in vitamin B12, and to a lesser extent 
vitamin B6 and riboflavin (Gibson, 2005a), renal impairment (van Guldener, 2006) 
and/or the use of certain medications, including diuretics and metformin (Ham et al., 
2014). Serum folate is considered an indicator of recent dietary intake whereas red 
blood cell folate reflects longer term folate status (Gibson, 2005a). The lack of 
consensus on which biomarker and cut-off values to use for these biomarkers together 
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with differences in assay methodology makes it challenging to compare results between 
different studies (de Jong et al.; Hausman et al., 2015). Cut-off values that are often 
used are < 6.8 nmol/L for serum folate and < 317 nmol/L for red blood cell (RBC) 
folate (Wright et al., 1998). These cut-off values were used in the National Nutrition 
Survey in New Zealand in 2008-2009 (University of Otago & Ministry of Health, 
2011). 
2.1.2 Folate status of older adults from national representative surveys 
Population folate status has been investigated in a number of national nutrition 
surveys (McLean, de Benoist, & Allen, 2008; Pfeiffer et al., 2007; University of Otago 
& Ministry of Health, 2011), including several countries prior to, and after the 
introduction of mandatory folic acid fortification of the food supply such as the United 
States (Pfeiffer et al., 2019). The primary reason for mandatory fortification with folic 
acid was to reduce the occurrence of neural tube defects in offspring due to inadequate 
intakes of folic acid in women of childbearing age (Crider, Bailey, & Berry, 2011). 
Other benefits of food fortification with folic acid include emerging evidence of the 
inverse association of folic acid uptake and homocysteine concentration and its related 
chronic diseases (Tinelli, Di Pino, Ficulle, Marcelli, & Feligioni, 2019).   
The most recent New Zealand Adult Nutrition Survey (NZ ANS) in 2008-2009, 
confirmed a very low prevalence ( 2%) of folate deficiency (defined as red blood cell 
folate < 317 nmol/L and serum folate < 6.8 nmol/L) in community-dwelling adults over 
the age of 71 years (University of Otago & Ministry of Health, 2011). It should be 
noted that the national survey was completed prior to an increased availability of 
voluntary folic acid fortification of commercial bread. Similarly, a very low prevalence 
of folate deficiency (< 1%) of non-institutionalised older adults (> 60 years) was shown 
in the United States in the National Health and Nutrition Examination Surveys 
(NHANES) post-fortification (1999-2010) (Pfeiffer et al., 2012; Pfeiffer et al., 2019). 
On the contrary, the UK National Diet and Nutrition Survey (2014/2015 to 2015/2016) 
(UK NDNS) found 14% of men and 10% of women over the age of 65 years with RBC 
folate deficiency (< 305 nmol/L) and 6% of men and women over the age of 65 years 
with a low serum folate (< 7 nmol/L) (Public Health England, 2018). The higher 
prevalence of folate deficiency amongst the UK population is likely due to the absence 
of mandatory folic acid fortification and variable uptake of the voluntary fortification 
policy. 
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2.1.3 Folate status of older adults from observational studies 
A number of observational studies have been conducted in New Zealand and 
other countries measuring the blood folate status of mostly community-dwelling older 
people. A study of 201 older adults living in Christchurch, 88% of them living in the 
community, found a very low prevalence of folate deficiency (1% serum folate < 4.3 
nmol/L and 3.3% red blood cell folate < 297 nmol/L) (Hanger, Sainsbury, Gilchrist, 
Beard, & Duncan, 1991). Of note, the cut-off value for serum folate used in this study 
was unusually low due to the use of the bio-rad assay. This method measures 35% 
lower folate values than the microbiological assay, accordingly a lower cut-off value 
(serum folate < 4.3 nmol/L) was used (Pfeiffer et al., 2016). The mean blood folate 
values were significantly lower for those living in a rest home compared to the 
community-dwelling participants [8.2 nmol/L and 11.3 nmol/L for serum folate (p < 
0.001) and 568 and 781 nmol/L for red cell folate (p < 0.001), respectively] (Hanger et 
al., 1991). Similarly, a low prevalence of folate deficiency was observed in a Dunedin 
study among 103 community-dwelling older women, where 4% had serum folate 
values < 6.7 nmol/L and 5% had red blood cell folate < 315 nmol/L (de Jong et al., 
2003). In contrast, a recent longitudinal cohort study termed The Life and Living in 
Advanced age study, a cohort study in New Zealand (LiLACS NZ) measured the folate 
status of Māori and non-Māori octogenarians, living in the community in the Bay of 
Plenty (Pillay et al., 2018). Findings revealed that almost one-third of Māori and non-
Māori men and women were folate deficient based on RBC folate < 317 nmol/L. 
Interestingly, serum folate deficiency (< 6.7 nmol/L) was rare (2% in non-Māori and 
0% in Māori participants).  
Similarly, the UK Newcastle 85+ study also showed a low prevalence of folate 
deficiency (3.6% RBC folate < 340 nmol/L) (Mendonça et al., 2016), whereas, over 
20% of adults over the age of 80 years in The Irish LongituDinal Study on Ageing 
(TILDA) had a folate deficiency (plasma folate < 10 nmol/L) (Laird et al., 2018). This 
higher level of folate deficiency in Ireland was also consistent with findings from the 
KORA-age study in Germany where approximately 20% had a serum folate < 13.6 
nmol/L in the 85 to 93-year old group (Conzade et al., 2017). Of note, the latter studies 
employed higher deficiency cut-off values.  
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2.1.4 Folate status of older adults living in residential aged care facilities 
Data on biochemical folate status in older adults residing in RACF are limited. 
In a cross-sectional study of 218 adults between 60 and 105 years of age in a rest home 
in Granada, Spain, 43.1% of participants exhibited a moderate folate deficiency (serum 
folate between 9.0-15.9 nmol/L) and 19.3% had a severe folate deficiency (serum folate 
 9.0 nmol/L) whereas hyperhomocysteinemia (homocysteine > 12 mol/L) was 
present in 80.7% participants (Gonzalez-Gross et al., 2007). Comparable results were 
found in another study in Northern Spain in seven nursing homes (n=140) where almost 
half of the participants were considered folate deficient (serum folate < 11 nmol/L) 
(Huerta et al., 2004). In contrast, in a study of 1885 institutionalised elderly in Hong 
Kong, approximately 12% of the 1885 participants had folate deficiency (serum folate 
< 6.8 nmol/L) (Wong et al., 2015). Similarly, few participants (5.9 %) were considered 
folate deficient (serum folate < 7.5 nmol/L) in a study of 84 older adults in rest homes 
in Portugal (Brito Noronha et al., 2015) and in Canada where a cross-sectional study of 
75 long-term care residents was undertaken (1.3% RBC folate < 370 nmol/L, serum 
folate was not measured) (Paulionis, Kane, & Meckling, 2005). 
No data on the biochemical folate status of older adults in residential aged care 
facilities in New Zealand are available except for the aforementioned study in 
Christchurch, which mostly included community-dwelling participants (Hanger et al., 
1991). 
2.2 Vitamin B12 
Vitamin B12 theoretically refers solely to cyanocobalamin but the term vitamin 
B12 is often used when referring to the different forms of cobalamin (Gibson, 2005a). 
Vitamin B12 is bound to protein in food and is solely found in animal products such as 
meat, fish, poultry, dairy product and eggs (The New Zealand Institute for Plant and 
Food Research & Ministry of Health, 2019). Furthermore, some foods in New Zealand 
such as breakfast cereals are fortified with vitamin B12 (The New Zealand Institute for 
Plant and Food Research & Ministry of Health, 2019). Fortified food contains 
cyanocobalamin which is converted to methylcobalamin and 5-
deoxyadenosylcobalamin – the biologically active forms of vitamin B12 (Smith, 
Warren, & Refsum, 2018). 
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5-Methylcobalamin functions as a cofactor for methionine synthase (MS), an 
enzyme required for remethylation of homocysteine. Ineffective functioning of this 
enzyme can lead to an increase of homocysteine. 5-Deoxyadenosylcobalamin serves as 
a cofactor for L-methylmalonyl-coenzyme A mutase which catalyses the conversion of 
L-methylmalonyl-coenzyme A (MMA) to succinyl-coenzyme A, an important enzyme 
in the synthesis of haemoglobin (Green et al., 2017).  
2.2.1 Biomarkers of vitamin B12 status and deficiency  
The main causes for vitamin B12 deficiency are inadequate intake and 
malabsorption (Allen et al., 2018). Suboptimal vitamin B12 intake in the elderly can be 
multifactorial due to: poor appetite, ill-fitting or ineffective dentures, vegetarianism, 
and/or dementia related food patterns (Amarya, Singh, & Sabharwal, 2015). 
Malabsorption can be caused by chronic atrophic gastritis (chronic inflammation with 
loss of parietal cells affecting 10-30% of elderly) (Institute of Medicine Food and 
Nutrition Board, 1998). In addition, common medication such as proton pump 
inhibitors which affect gastric hydrochloric acid production have been implicated in 
some studies; however, other studies have found no relationship between these 
medications and vitamin B12 deficiency (Allen et al., 2018; Masclee, Sturkenboom Mc 
Fau - Kuipers, & Kuipers, 2014).  
Clinical stages of vitamin B12 deficiency progress as follows: firstly, an 
increase in plasma MMA followed by a decrease of serum holotranscobalamin 
(holoTC) and serum vitamin B12 with a rise of plasma homocysteine. Furthermore, a 
decrease of red blood cell vitamin B12, and hypersegmentation of nuclei in neutrophils 
leads to megaloblastic anaemia. Vitamin B12 deficiency is also associated with 
neurological symptoms, cognitive decline, dementia and depression (Allen et al., 2018).  
Serum or plasma total vitamin B12 concentration reflect long-term vitamin B12 
status and is the biomarker most often used to determine deficiency, despite both poor 
sensitivity and specificity (Smith, Warren, et al., 2018). The most commonly used cut-
off for deficiency is serum vitamin B12 < 148 pmol/L, with marginal status indicated 
by serum concentrations between 148-221 pmol/L and sufficiency > 221 pmol/L (Allen 
et al., 2018). Serum holoTC transports active cobalamin and is considered a potentially 
better marker of the metabolic function of vitamin B12. Serum methylmalonic acid 
(MMA), a more specific and sensitive biomarker of vitamin B12 status, reflects the 
function of methylmalonyl CoA mutase which requires vitamin B12 as a cofactor. 
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Lastly, homocysteine is a sensitive but not specific biomarker for vitamin B12 
deficiency as it may also increase in folate, vitamin B6 and riboflavin deficiency (Allen 
et al., 2018; Smith, Warren, et al., 2018) 
Serum vitamin B12 as a stand-alone marker is not considered specific and 
sensitive enough for the unequivocal diagnosis of vitamin B12 deficiency. Lately, 
algorithms or models which utilise multiple biomarkers to more accurately diagnose 
vitamin B12 deficiency have been developed (Allen et al., 2018). One of these 
sequential algorithms use serum vitamin B12 as the initial measurement and if found to 
be below 148 pmol/L, then participants are classified as at risk of a vitamin B12 
deficiency. If, vitamin B12 status is classified as indeterminate (serum vitamin B12 
between 148 and 250 pmol/L, indicating vitamin B12 depletion and, for some, probably 
deficiency) then an additional functional indicator such as homocysteine is used. Where 
homocysteine is raised (> 15 mol/L), vitamin B12 deficiency is confirmed (Allen et 
al., 2018).  
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2.2.2 Vitamin B12 status of older adults from national representative 
surveys 
Figure 2.1 shows the prevalence of deficient and marginal vitamin B12 status in older 
adults from selected national nutrition surveys and large population studies. 
 
Figure 2.1 Vitamin B12 status of older adults in national nutrition surveys and large 
population studies  
(Allen et al., 2018; Clarke et al., 2004; Green et al., 2017; MacFarlane, Greene-
Finestone, & Shi, 2011; McLean et al., 2008). 
Prevalence of low (blue < 148 pmol/L) and marginal (orange 148-221 pmol/L) serum vitamin B12 
except TILDA where marginal status was defined as < 185pmol/L. 
Abbreviations: NZ NNS, New Zealand National Nutrition Survey; CHMS, Canadian Health Measures 
Survey; US NHANES, United States National Health and Nutrition Examination Survey; TILDA, The 
Irish Longitudinal Study on Ageing; UK MRC, United Kingdom Medical Research Council; UK NDNS, 
United Kingdom National Diet and Nutrition Survey; UK OHAP, United Kingdom Oxford Healthy 
Aging Project.  
 
The prevalence of vitamin B12 deficiency in older adults varies widely. In the 
New Zealand National Nutrition Survey (NZ NNS) 1996-1997, the prevalence of 
deficiency was 12% among community-dwelling older adults, whereas more than 
double (28%) had a marginal status (Green, Venn, Skeaff, & Williams, 2005). The 
prevalence of deficiency in the NZ ANS 2008-2009 was not reported but mean serum 
0 5 10 15 20 25 30 35 40 45
UK OHAP (1991-1994)(>65y)
UK NDNS  (1994-1995)(>65y)
UK MRC (1995-1999)(>75y)
TILDA 2009-2011
US NHANES III (1988-1994)(60-69y)
US NHANESIII (1988-1994)(>70y)
CHMS (2007-2009) (60-79y)
NZ NNS (1996-1997) (>65y)
Prevalence of low and marginal serum B12 (%)
Serum B12<148pmol/L Serum B12 148-221 pmol/L
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vitamin B12 was 323 pmol/L (95% CI 310-337pmol/L) and 300 pmol/L (95% CI 283-
316 pmol/L) in the 65-75 years and > 75 age group respectively, well above the cut-off 
for vitamin B12 sufficiency (Devi, Rush, Harper, & Venn, 2018). NHANES 2003-2006 
confirmed a low prevalence (3.9%, 95% CI 3.1- 4.9) of vitamin B12 deficiency in 
adults aged 60 years and older (Pfeiffer et al., 2007). The UK Oxford Healthy Aging 
Project (OHAP) (1991-1994) included only a small proportion of RACF residents (1% 
of 65-74 years old and 6% of those aged 75 years and older), with 0% and 7% 
exhibiting deficiency, respectively (Clarke et al., 2004). In contrast, the UK National 
Diet and Nutrition Survey (NDNS) (1994-1995) included a higher proportion of RACF 
residents (9% < 75 years and 30% > 75 years), with a higher prevalence of vitamin B12 
deficiency (13% and 22% respectively). In the latter study, there was no significant 
difference in the prevalence of deficiency between the RACF residents and community-
dwelling older adults > 75 years of age (12% and 26%) (Clarke et al., 2004). The Irish 
Longitudinal study of Ageing (TILDA) reported a substantially lower prevalence of 
marginal vitamin B12 status (7%), however this is likely due to a higher cut-off value 
(< 185 pmol/L) (Laird et al., 2018). Nonetheless, all three UK studies exhibited an 
increased prevalence of vitamin B12 deficiency with increasing age (Clarke et al., 
2004). To this end, the higher prevalence of vitamin B12 deficiency (16%) found in the 
UK Medical Research Council (MRC) study is likely explained by the older age group 
of participants (> 75 years). Moreover, the high prevalence of vitamin B12 deficiency 
in the UK NDNS may also be due to the use of a different assay methods compared to 
UK OHAP and UK MRC (Clarke et al., 2004). 
2.2.3 Vitamin B12 status of community-dwelling older adults from 
observational studies  
Table 2.1 summarises the prevalence of vitamin B12 deficiency of community- 
dwelling older adults from cross-sectional studies, ranging between 3% and 25%. 
Similar to the UK NDNS and UK MRC study, the UK Newcastle 85+ study reported a 
high prevalence of vitamin B12 deficiency (17.1%) however, participants were 85 
years or older (Mendonça et al., 2016). In contrast, a multicenter study The Survey in 
Europe Nutrition and the Elderly, a concerted Action (SENECA) study, reported 
vitamin B12 deficiency of 2.7% among participants aged 70-75 years albeit the cut-off 
was very low (serum vitamin B12 < 111 pmol/L) (de Groot, Hautvast, & van Staveren, 
1992). Studies done to date in New Zealand (n=3) have all reported a relatively low 
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prevalence of vitamin B12 deficiency ranging from 7% to 13% (de Jong et al., 2003; 
Hanger et al., 1991; Pillay et al., 2018). Of note, one of the studies conducted in New 







Table 2.1 Prevalence of vitamin B12 deficiency in community-dwelling older adults worldwide 
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2.2.4 Vitamin B12 status of older adults in residential aged care facilities  
Table 2.2 gives an overview of the prevalence of vitamin B12 deficiency in 
older adults in RACF. The prevalence of deficiency in this residential population, with 
cut-off values for deficiency varying from < 148 pmol/L to < 156 pmol/L, ranges from 
5% to 35%. The prevalence of marginal vitamin B12 status ranges from 14% to 43% 
but cut-off values vary more widely, thus making comparisons among studies difficult. 
The largest study to date conducted in China (n 1996, average age 83 years), reported 
almost one-third of participants having a vitamin B12 deficiency. This latter 
retrospective study was completed by reviewing clinical records of residents who had a 
vitamin B12 measurement taken between 2011-2013; supplement users were excluded 
(Wong et al., 2015).  
Only two studies describe vitamin B12 status in RACF residents in New 
Zealand. A study conducted in Christchurch, including RACF participants (shown in 
Table 2.1) reported a low prevalence of deficiency (7%), with no difference seen 
between community dwelling and rest home participants, albeit the cut-off used was 
very low (< 114 pmol/L) as mentioned previously (Hanger et al., 1991). The other 
study, conducted in Auckland among rest home and geriatric ward residents (Table 2.2) 
revealed 23% vitamin B12 deficiency (serum vitamin B12 < 135 pmol/L), with 33% 
and 13% in rest home and geriatric ward residents, respectively (Barber, Christie, 
Thula, & Cutfield, 1989). 
 





Table 2.2 Prevalence of vitamin B12 deficiency in older adults in residential aged care facilities worldwide 
Author Country n Age, (years) 
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Abbreviations: NH, nursing home; LTCH, long-term care hospital; RACF, residential aged care facility; LTCR, long-term care residence; EH, elderly home; ER, elderly care 
residency; CF, care facility; CHS, care homes; GW, geriatric ward 
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2.3 Riboflavin  
Riboflavin (vitamin B2) is a water-soluble vitamin and is a precursor of two 
coenzymes, flavin mononucleotide (FMN) and flavin adenine dinucleotide (FAD). 
Both FAD and FMN function as cofactors for several enzymes such as glutathione 
reductase (involved in redox reactions) and 5,10-methylenetetrahydrofolate reductase 
(involved in one-carbon metabolism). FMN is also needed in the conversion of vitamin 
B6 to pyridoxal-5’-phoshate (Gibson, 2005b). Most of the riboflavin in our diet is 
present in the FAD form with smaller amounts as FMN and free riboflavin (Pinto & 
Zempleni, 2016). 
The major food group sources of riboflavin are milk, organ meats, lean meats, 
eggs, yeast and green vegetables (The New Zealand Institute for Plant and Food 
Research & Ministry of Health, 2019). In New Zealand, breakfast cereals, some 
biscuits, bread, flours, pasta and dried milks are permitted for fortification with 
riboflavin (Food Standards Australia and New Zealand, 2016).  
2.3.1 Biomarkers of riboflavin and deficiency 
Body stores of riboflavin are minimal. Inadequate intake is the main cause of 
riboflavin deficiency but other disorders such as chronic alcoholism, hypothyroidism 
and adrenal insufficiency can also affect riboflavin status (Gibson, 2005a). Typical 
signs of riboflavin deficiency are angular stomatitis (inflammation of the corner of the 
mouth), glossitis (inflammation of the tongue), cheilosis (inflammation of the lips) and 
inflamed mucosa of mouth and throat (Thurnham, 1981). 
Riboflavin status is assessed via the measurement of the erythrocyte glutathione 
reductase activation coefficient (EGR-AC) in washed red blood cells (McNulty, Strain, 
& Hoey, 2009). The activity of glutathione reductase is measured in-vitro before and 
after adding of FAD to red blood cells. The EGR-AC is calculated as the ratio of 
stimulated over unstimulated enzyme activity, with a higher EGR-AC indicating poorer 
riboflavin status. There is, however, no consensus regarding the cut-off value for 
abnormal EGR-AC (Hill, Bradley, Mushtaq, Williams, & Powers, 2008); cut-off values 
typically used to indicate deficient, marginal and adequate status are >1.4, 1.2-1.4 and 
< 1.2, respectively (McCormick, 1972). 
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2.3.2 Riboflavin status of older adults from national representative 
population surveys 
Riboflavin status in older adults has not been studied widely. While the majority 
of population-based surveys estimate dietary riboflavin intake, only a few have also 
assessed biochemical riboflavin status. A recent report from the UK NDNS showed that 
around 40% of men and women above the age of 65 years had an EGR-AC  1.3 
considered to be riboflavin depleted (Public Health England, 2016). In contrast, the 
Elderly Nutrition and Health Survey in Taiwan (n 2379) found only around 5% of the 
sample population over the age of 65 years were riboflavin deficient (defined as EGR-
AC ≥ 1.4) while almost 25% had a marginal riboflavin status (defined as 1.2 ≤ EGR-
AC <1.4) (Yang, Liao, Chen, Wang, & Shaw, 2005).  
2.3.3 Riboflavin status of older adults from cross-sectional studies 
In smaller studies conducted in healthy older adults living independently in 
Germany (n 277) (Hahn, Hermann, & Wolters, 2003) and Spain (n 133) (Lopez-
Sobaler et al., 2002), 6.2% and approximately 10% were classified as riboflavin 
deficient, respectively. Comparing these studies is difficult as cut-off values used for 
defining riboflavin status differed. 
Few studies have examined biochemical riboflavin status in older adults in 
RACF.  Of those, a recent study in British Columbia, Canada in 5 RACF found a fairly 
high prevalence of riboflavin deficient or marginal status among the sample population, 
with a quarter of the 207 participants exhibiting deficiency (EGR-AC 1.4) and 14% 
deemed marginal (EGR-AC 1.3 to  1.4) (Whitfield et al., 2018). Similarly, a small 
study in France (n 26) found almost half of their residents were classified as riboflavin 
deficient however, the EGR-AC used to define deficiency was lower than most studies 
(cut-off value EGR-AC >1.19) (Essama-Tjani, Fuchs, Lombard, & Richard, 2000).  
To date, there are no data available of biochemical riboflavin status of older 
adults living in RACF in New Zealand. 
2.4 Vitamin B6 
Vitamin B6 (B6) is a generic name representing six interconvertible water-
soluble compounds: pyridoxal (PL), pyridoxine (PN) and pyridoxamine (PM), the three 
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forms mainly found in food, and their phosphorylated forms, pyridoxal 5’-phosphate 
(PLP), pyridoxine-5’-phoshate (PNP) and pyridoxamine-5’-phosphate (PMP) (Gibson, 
2005c). PLP and PMP are the active cofactors of vitamin B6. PLP is the most crucial 
form and is a cofactor for many enzymes involved in amino acid and protein 
metabolism (Percudani & Peracchi, 2009). PLP is also a coenzyme for cystathione--
synthase and -cystathionase, enzymes involved in metabolising homocysteine through 
the trans-sulphuration pathway in one-carbon metabolism (Selhub, 2002).  
Vitamin B6 is found in a variety of foods. Fish, organ meats, starchy vegetables 
such as potatoes and some fruits such as banana are rich sources of vitamin B6 (The 
New Zealand Institute for Plant and Food Research & Ministry of Health, 2019). Some 
countries such as the United States fortify foods such as breakfast cereals with vitamin 
B6 (Wiemer, 2018). In New Zealand, fortification with vitamin B6 is permitted for 
breakfast cereals, biscuits, bread, flours and pasta (Food Standards Australia and New 
Zealand, 2016).  
2.4.1 Biomarkers of vitamin B6 and deficiency  
Body stores of vitamin B6 are minimal (Spinneker et al., 2007). Vitamin B6 
deficiency can occur due to suboptimal intake in addition to protein-energy 
undernutrition, malabsorption, alcoholism and some drugs (anti-convulsant, isoniazid 
and steroids) (Porter et al., 2016). Non-specific symptoms of vitamin B6 deficiency are 
headaches and fatigue, skin and mouth mucosal lesions, convulsions and depression 
(Gibson, 2005c). 
There are different ways to measure vitamin B6 status either as a direct marker 
or as a functional marker. Plasma pyridoxal 5’phosphate (PLP) is the most commonly 
used nutritional direct biomarker, with a cut-off < 20 nmol/L indicating deficiency 
(Ueland, Ulvik, Rios-Avila, Midttun, & Gregory, 2015). A number of indirect 
functional markers measuring PLP-dependent enzyme activity, are considered 
indicative of long-term vitamin B6 status indicator. For example, aspartic acid 
transaminase (AST, EC 2.6.1.1) also known as glutamate oxaloacetate transaminase, 
requires PLP as cofactor to function. The activity of AST is measured before and after 
in vitro addition of PLP in washed red blood cells. Erythrocyte AST activity coefficient 
(EAST-AC) is calculated as the ratio of stimulated over unstimulated enzyme activity. 
A higher EAST-AC means a lower vitamin B6 status. There is no consensus regarding 
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cut-off values for EAST-AC but often deficiency is defined as >1.85, marginal 1.7-1.85 
and sufficient < 1.7 (Sauberlich, 1999). 
2.4.2 Vitamin B6 status of older adults from national representative 
surveys 
Most population-based surveys have only investigated dietary intake of vitamin 
B6 with few assessing vitamin B6 status in community-dwelling older adults  65 years 
of age. Most of these surveys show that vitamin B6 deficiency (PLP < 20 nmol/L) is 
widespread in older adults. The Survey in Europe Nutrition and the Elderly, a 
Concerted Action (SENECA) showed vitamin B6 deficiency in 22% of both male and 
female older adults (van der Wielen et al., 1996). Similarly, NHANES in the US 
confirmed almost a quarter of older adults over the age of 65 years were vitamin B6 
deficient when not using vitamin B6 supplements, whereas, deficiency was found in 
only 6% of supplement users (Morris, Picciano, Jacques, & Selhub, 2008). Conversely, 
The National Diet and Nutrition Survey (NDNS) (2008/2009-2011-2012) from the UK 
showed mean values of plasma PLP of 46.1 nmol/L for men and 55.2 nmol/L for 
women over the age of 65 years. The prevalence of vitamin B6 deficiency was not 
reported in the latter study however, mean PLP values were well above typical 
deficiency cut-offs of PLP < 20 nmol/L (Public Health England, 2014). Biochemical 
vitamin B6 status has not been measured in either of the national nutrition surveys in 
New Zealand. 
2.4.3 Vitamin B6 status of older adults from observational studies 
Data are limited regarding the biochemical vitamin B6 status in older adults 
living in RACF. The UK National Diet and Nutrition Survey in 1994-1995 included 
aged care residents (n 256) and found that 75% were vitamin B6 deficient  
(PLP < 30 nmol/L) (Bates, Pentieva, Prentice, Mansoor, & Finch, 1999). A high 
prevalence of vitamin B6 deficiency (49%) was also found in a cross-sectional study of 
61 older adults across five Norwegian nursing homes (PLP < 20 nmol/L) (Kjeldby et 
al., 2013). In contrast, a study in Granada, Spain among 218 participants in one rest 
home found only one participant with vitamin B6 deficiency (< 20 nmol/L). This latter 
study measured total vitamin B6 making it difficult to compare to the other studies 
(Gonzalez-Gross et al., 2007). Furthermore, a cross-sectional study looking at vitamin 
B6 status in 75 participants in long-term hospital care in Guelph, Ontario showed 
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vitamin B6 deficiency in 5.3% of participants (PLP < 30 nmol/L) (Paulionis et al., 
2005).  
No data are available of the prevalence of vitamin B6 deficiency in the older 
adults in RACF in New Zealand. 
2.5 One- carbon metabolism and the role of metabolically 
related B-vitamins 
Folate, vitamin B12, vitamin B6 and riboflavin are nutrients required for the 
efficient functioning of one-carbon metabolism as depicted in Figure 2.2. One-carbon 
metabolism encompasses a complex pathway of interrelated biochemical reactions that 
deliver one carbon moieties (methyl groups) to many biologic reactions, including 
DNA synthesis and methylation (Suh, Choi, & Friso, 2016). Homocysteine, an 
intermediary in one-carbon metabolism which is consequently influenced by B-vitamin 
status, has been linked to common conditions associated with ageing. These conditions 
include depression, diabetes and stroke 
2.5.1 The one carbon metabolic pathway 
One-carbon metabolism involves three intersecting pathways: a folate cycle, a 
methylation cycle and a trans-sulphuration pathway (Blom & Smulders, 2011). Folate 
and choline (via its breakdown product betaine) function as one-carbon donors, and 
vitamin B12, vitamin B6 and riboflavin act as cofactors for enzymes involved in these 
pathways (Suh et al., 2016). Suboptimal status of these nutrients can result in a rise of 
homocysteine, a non-protein-forming, sulfur-containing amino acid that functions as a 
key intermediate in methionine metabolism (Jacques et al., 2001; Konstantinova et al., 
2007; Miller, 2013) 
The main form of folate found naturally in the diet is 5-methyltetrahydrofolate 
(5-methylTHF). Folic acid, the synthetic form of folate is reduced to dihydrofolate 
(DHF) and subsequently to tetrahydrofolate (THF) to enter the folate cycle (Figure 2.2). 
THF is converted to 5,10-methyleneTHF in a vitamin B6 dependent reaction, using 
serine as a carbon donor. Thereafter, 5,10-methylene THF is either converted to 5-
methylTHF catalysed by methylenetetrahydrofolate reductase (MTHFR) in a riboflavin 
dependent reaction linking the folate cycle to the methionine cycle or 5,10-
methyleneTHF can be used in the formation of purine and thymidine essential for DNA 
and RNA synthesis and repair (Mahmood, 2014). 
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In the methylation cycle, a methyl group from 5-methylTHF is transferred to 
homocysteine to form methionine in a reaction catalysed by the enzyme methionine 
synthase (MS) and needing vitamin B12 as a cofactor (Suh et al., 2016) (Figure 2.2). 
Methionine is then used for the synthesis of S-adenosylmethionine (SAM), the 
universal one-carbon donor for methylation of DNA, RNA, phospholipids, 
neurotransmitters and proteins (Chiang et al., 1996). Subsequently, SAM is converted 
to S-adenosylhomocysteine (SAH) which is further hydrolysed to homocysteine (Scott 
& Weir, 1998). Another way of remethylating homocysteine to methionine, mainly in 
the liver and kidneys, is in a folate independent reaction catalysed by the enzyme 
betaine-homocysteine methyltransferase which uses betaine, a breakdown product of 
choline, as a methyl group donor (Eussen et al., 2007; Finkelstein & Martin, 2000). 
In the trans-sulphuration pathway, homocysteine is diverted from the 
methylation cycle and irreversibly degraded to cystathionine by cystathionine--
synthase and further to cysteine by -cystathionase both vitamin B6 dependent enzymes 
(Finkelstein & Martin, 2000) (Figure 2.2).   
 
  
     

































Abbreviations: B2, vitamin B2 or riboflavin; B6, vitamin B6; B12, vitamin B12; DHF, dihydrofolate; THF, 
tetrahydrofolate. Adapted from (Porter, Hoey, Hughes, Ward, & McNulty, 2016) 
Figure 2.2 One-carbon metabolism 
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Thus, homocysteine is a key intermediate in the one-carbon pathway, with 
folate, vitamin B12 and, to a lesser extent, vitamin B6 and riboflavin considered to be 
the main nutritional predictors of circulating homocysteine levels (Holm Pål et al., 
2005; Holm et al., 2007; Jacques et al., 2001; Konstantinova et al., 2007; Mahmood, 
2014; Miller, 2013; Refsum et al., 2004). Furthermore, betaine, a nutrient obtained 
from foods, such as wheat bran, wheat germ, spinach, beets and sea food, or through 
the irreversible oxidation of choline, has been identified as a predictor of homocysteine 
(Holm Pål et al., 2005; Holm et al., 2007; Imbard et al., 2013). Betaine, as with folate 
(with or without vitamin B12 and vitamin B6), has been shown in several RCT’s to 
lower fasting homocysteine (Olthof, Bots, Katan, & Verhoef, 2006; Olthof, van Vliet, 
Boelsma, & Verhoef, 2003; Schwab et al., 2002; Steenge, Verhoef, & Katan, 2003).  
Choline is the precursor of betaine, acetylcholine and phospholipids and can be 
obtained through food (eggs, liver, milk, red meat, fish and poultry) or synthesised de 
novo from phosphatidylethanolamine (Wallace et al., 2018). A number of observation 
studies have shown an inverse association between choline intake and plasma 
homocysteine (Chiuve et al., 2007; Cho et al., 2006; Lee et al., 2010). Conversely, no 
association was found between choline intake and plasma homocysteine in individuals 
without MTHFR gene mutation (MTHFR 677 CC) in a 12-week controlled feeding 
study in healthy Mexican-American men consuming 300, 550, 1100, or 2200 mg 
choline/day; in contrast, a positive association was present in those individuals with the 
gene mutation (MTHFR 677 TT) (Caudill et al., 2009). The reason for this finding was 
unknown. Other studies examining the effect of choline supplementation on fasting 
homocysteine have shown conflicting results. In an RCT in 42 postmenopausal women 
60 years of age, fasting homocysteine was not significantly lowered in the intervention 
group taking 1 g choline per day for 12 weeks compared to placebo (Wallace et al., 
2012). Meanwhile, a study in 26 men with a mean age of 61 years, fasting 
homocysteine decreased by 18% after ingesting 2.6 g choline per day for 2 weeks 
(Olthof, Brink, Katan, & Verhoef, 2005). Studies examining plasma free choline as a 
predictor for homocysteine are limited. In a study in 108 participants 18-62 years of age 
choline was positively associated to betaine but no relationship was observed with 
plasma homocysteine. (Imbard et al., 2013).  
Alongside various nutritional determinants of homocysteine, numerous of non-
nutritional determinants have been identified. Plasma homocysteine increases with age 
(Jacques et al., 2001; Nygård, Refsum, Ueland, & Vollset, 1998; Yao et al., 2017), is 
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higher in males (Wang, Zhang, Wang, & Li, 2017), rises in renal dysfunction (van 
Guldener, 2006) and is influenced by medications such as diuretics and metformin 
(Ham et al., 2014). Sedentary lifestyle, caffeine intake, smoking and alcohol 
consumption may also increase homocysteine as well (Jacques et al., 2001; Nygård et 
al., 1998; Refsum et al., 2006). Moreover, genetic mutations such as homozygosity for 
MTHFR 677C→T polymorphism, resulting in reduced enzymatic activity can also 
cause hyperhomocysteinemia (HHcy) (Refsum et al., 2006).  
A threshold for HHcy of 13 mol/L has been used in some studies (Smith, 
Refsum, et al., 2018). However, in the majority of studies HHcy is defined as >15 
mol/L whereas 15-30 mol/L is considered mild HHcy, 30-100 mol/L moderate and 
> 100 mol/L severe HHcy (Price, Wilcock, & Weekman, 2018). Prevalence of 
hyperhomocysteinemia increases with age, ranging between 40 and 80% in older adults 
in RACF (Ao et al., 2019; Gharaibeh et al., 2010; Gonzalez-Gross et al., 2007; Huerta 
et al., 2004; Paulionis et al., 2005) albeit cut-off values differ among studies. 
HHcy has been associated with cardiovascular diseases such as stroke (CVD), 
cognitive impairment and dementia (Kim et al., 2013; Smith et al., 2010; Xu et al., 
2015) depression (Kim et al., 2008), type 2 diabetes (Huang , Ren, Huang, & Li, 2013), 
osteoporosis (Behera, Bala, Nuru, Tyagi, & Tyagi, 2017) and cancer (Hasan et al., 
2019). Multiple studies have confirmed the homocysteine-lowering effect of folic acid 
supplements with or without vitamin B12 and vitamin B6 (Clarke, Lewington S Fau - 
Sherliker, Sherliker P Fau - Armitage, & Armitage, 2007; Homocysteine Lowering 
Trialists’ Collaboration, 2005; Smith et al., 2010). Nonetheless, studies exploring the 
clinical effects of these homocysteine-lowering treatments are conflicting. 
 
2.5.2 Homocysteine and diseases  
For the purpose of the thesis, the emerging evidence linking homocysteine and 
the degenerative diseases in ageing of stroke, diabetes and depression will be reviewed 
2.5.2.1 Homocysteine and stroke 
 
Cerebrovascular accidents (CVA or stroke) are the second leading cause of 
death globally, and a major cause of disability (World Health Organisation, 2017). In 
New Zealand, more than 7000 people suffered a stroke in 2015 (Ranta, 2018). A stroke 
is caused by a disruption of blood flow to part of the brain, which causes brain cells to 
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be damaged or die. This phenomenon occurs when an artery within the brain ruptures 
and bleeds (haemorrhagic stroke) or more commonly, when a blood clot completely 
blocks an artery in, or to the brain (ischaemic stroke). A mini stroke, or transient 
ischaemic attack (TIA), occurs when blood flow to the brain is temporarily disrupted 
due to a narrowing of an artery in, or to the brain, or as a result of a blood clot that 
quickly dislodges (Hankey, 2017). 
The prevalence of stroke increases with age (North & Sinclair, 2012) along with 
other typical cardiovascular risk factors including smoking, hypertension, diabetes, 
lipid abnormalities, sedentary lifestyle and obesity (National Institute of Neurological 
Disorders and Stroke, 2019). Multiple observational studies have shown a positive 
association between hyperhomocysteinemia and stroke risk (Bos, van Goor, Koudstaal, 
& Dippel, 2005; Bostom et al., 1999; Sacco et al., 2004; Virtanen et al., 2005; Zhang et 
al., 2009). Homocysteine at excess levels is a toxic metabolic intermediate that 
interferes with proper redox balance and increases oxidative stress and the production 
of free radicals (Ganguly & Alam, 2015; Lehotský et al., 2016). Nonetheless, it is 
unclear whether high circulating levels of homocysteine directly contribute to the 
pathophysiology of stroke or merely represents a biomarker of metabolic aberrations 
that are associated with impaired DNA methylation (Ganguly & Alam, 2015).  
Strategies to reduce plasma homocysteine concentrations have reached 
nonconclusive clinical results. For example, while folic acid supplementation with or 
without vitamin B12 and vitamin B6 has shown to decrease homocysteine 
concentrations up to 28% (Miller, 2013) randomised placebo-controlled trials assessing 
the effect of homocysteine-lowering interventions on stroke are inconsistent. The 
majority of supplementation trials indicate no significant overall risk reduction of 
stroke in the intervention group compared to the control group (Albert et al., 2008; 
Almeida et al., 2010; Bonaa et al., 2006; Ebbing et al., 2008; Hodis et al., 2009; Liem 
et al., 2004; Toole et al., 2004; van Dijk et al., 2015). Studies to date that have found 
significant risk reduction in stroke include the China Stroke Primary Prevention Trial 
(CSPPT) (Huo et al., 2015), the largest double-blinded RCT on the effect of folic acid 
supplementation on primary stroke prevention. Findings from this trial found protective 
effects of homocysteine-lowering supplementation strategies when combined with 
other therapeutic treatment. Of note, the CSPTT examined the effect of enalapril (ACE 
inhibitor) alone versus enalapril with folic acid (0.8 mg/d) on stroke incidence in a total 
of 20702 hypertensive participants. After a median follow-up of 4.3 years, the enalapril 
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with folic acid group had a 21% risk reduction in first stroke (HR 0.79; 95% CI, 0.68-
0.93). It should also be noted that China does not have a mandatory folic acid food 
fortification programme; and as such, there was a considerable variation in plasma 
folate levels. The greatest benefit on stroke reduction in CSPPT was observed in 
participants with the lowest blood folate levels (Huo et al., 2015). These findings 
suggest that improving folate status rather than lowering homocysteine concentration 
may be the mode of action. The CSPPT has been included in a recent Cochrane review 
which encompassed 14 other RCT’s examining the effect of homocysteine lowering 
treatment (folic acid with or without vitamin B12 and vitamin B6 supplements) on 
CVD and stroke (Martí‐Carvajal, Solà, Lathyris, & Dayer, 2017). Results of the meta-
analysis concluded that homocysteine-lowering interventions compared to placebo 
were associated with reduced stroke risk RR 0.90 (95% CI 0.82-0.99) (Martí‐Carvajal 
et al., 2017).  
In contrast, the VITAmins TO Prevent Stroke trial (VITATOPS) (The 
VITATOPS Trial Study Group, 2010), investigated the preventive effect of folic acid 
with vitamin B6 and vitamin B12 on recurrent stroke or TIA in participants with recent 
stroke or TIA. VITATOPS showed no overall risk reduction of recurrent stroke in the 
intervention group compared to the placebo group; however, in a post-hoc sub-analysis 
a 35% risk reduction for stroke was found (HR 0.65; 95% CI 0.46, 0.91) in the 
intervention subgroup not receiving antiplatelet therapy (Hankey et al., 2012). 
Similarly, the Heart Outcome Prevention Evaluation 2 trial (Hope 2) (Saposnik, Ray , 
Sheridan, McQueen, & Lonn, 2009) a multicentre international trial including 5522 
participants with known cardiovascular disease, demonstrated a stroke risk reduction of 
25 % (HR 0.59-0.96) among the intervention group supplemented with folic acid, 
vitamin B6 and vitamin B12 compared to placebo. The magnitude of effect in the latter 
study was greater among participants who were not receiving lipid-lowering medication 
or antiplatelet treatment in addition to those less than 69 years of age, from regions 
without folic acid fortification, and in participants with higher baseline homocysteine 
and cholesterol levels (Saposnik et al., 2009).  
The use of homocysteine-lowering B-vitamins in addition to drug management 
may benefit certain population stroke subgroups. However, the differences in the trials 
to date such as varying supplement dosages, patient differences in risk factors or 
medical history and other confounding factors, make it difficult to develop universal 
guidelines.
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2.5.2.2 Homocysteine and depression 
 
Depression is a common disorder among older adults. The LILAC study in New 
Zealand, classified approximately 20% of community-dwelling octogenarians as 
depressed (GDS +5) (Atlas, Kerse, Rolleston, Teh, & Bacon, 2017). Additionally, a 
large body of evidence demonstrates significantly greater risk of depression for those 
who reside in residential aged care (Blazer, 2003; Simning & Simons, 2017; Teresi, 
Abrams, Holmes, Ramirez, & Eimicke, 2001). For example, approximately 50% of 
aged care residents in Australia exhibited symptoms of depression according to a 2013 
Australian Institute of Welfare report (Australian Institute of Health and Welfare, 
2013).  
Both sociological and physiological factors have been associated with 
depression including loneliness, lack of social support, functional limitations, stroke, 
visual impairment and recent negative life events (Jongenelis et al., 2004). Biochemical 
changes in the brain, genetics and personality may also play a role in depression 
disorders in addition to low folate and vitamin B12 status as well as elevated 
homocysteine levels (Bjelland, Tell , Vollset, Refsum, & Ueland, 2003; Kim et al., 
2008; Moore et al., 2019; Tiemeier et al., 2002). 
One of the possible mechanisms explaining the association between elevated 
homocysteine levels and depression is related to a decrease in S-adenosylmethionine 
(SAM) (Bottiglieri et al., 2000). SAM plays an important role in the production of 
neurotransmitters, such as serotonin, dopamine, noradrenaline and melatonin. A 
disturbance of these neurotransmitters can influence mood and lead to depression (Nutt, 
2008). In addition, homocysteine is shown to be neurotoxic at excess levels by inducing 
oxidative stress, apoptosis and DNA strand breakage (Bhatia & Singh, 2015).  
Several randomised controlled trials have examined the effect of homocysteine-
lowering interventions with folic acid with, or without vitamin B12 and vitamin B6 on 
depression. Almeida and colleagues included 11 of these placebo-controlled RCT’s in a 
recent review and meta-analysis (Almeida, Ford, & Flicker, 2015). Summary statistics 
revealed no beneficial effect of folate and vitamin B12 supplementation on depressive 
symptoms in adults with and without a major depressive episode at the time of 
randomisation. In contrast, trials looking at the adjunct effect of B-vitamin supplements 
to antidepressant medication in people with depression show conflicting results. For 
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example, Coppen et al. added 0.5mg of folic acid for 10 weeks to fluoxetine, a selective 
serotonin re-uptake inhibitor antidepressant. The addition of folic acid led to a 
significant improvement in depression (as measured by the Hamilton Depression 
Rating Scale) in women compared to the group with fluoxetine treatment only (Coppen 
& Bailey, 2000). In contrast, the B-VITAGE study, a randomised double-blind, 
placebo-controlled trial in 153 middle-aged and older adults, looked at the effect of 
citalopram (another selective serotonin re-uptake inhibitor) with or without 0.5 mg 
vitamin B12, 2 mg folic acid and 25 mg vitamin B6 supplements for 52 weeks. The 
efficacy of treatment with or without supplements was not significantly different 
between the two groups. However, among participants who were no longer depressed 
by week 12, relapse of symptoms was less frequent at week 26 and week 52 in the 
intervention group compared to placebo (OR 0.33, 95% CI 0.12-0.94) (Almeida et al., 
2014). 
To date, there are only two RCT’s which have investigated the homocysteine-
lowering effect of B-vitamins on the prevention of clinically significant symptoms of 
depression in at risk older adults. A secondary investigation in the VITATOPS study 
(VITATOPS-DEP) confirmed a 52% reduction in the risk of major depressive episodes 
in the intervention group who received folic acid (2 mg), vitamin B6 (25 mg) and 
vitamin B12 (0.5 mg) compared to placebo (HR 0.48, 95% CI 0.27-0.86) (Almeida et 
al., 2010). In contrast, Ford et al. in a 2-year RCT in 299 men aged 75 years and older 
showed that supplementation with 2 mg folic acid, 0.4 mg vitamin B12 and 25 mg 
vitamin B6 was not better in reducing the incidence of depression than placebo (Ford et 
al., 2008).  
In summary, folic acid with or without vitamin B12 and vitamin B6 may be 
efficacious, although findings are difficult to compare due to methodological study 
differences, and variation in population sample groups and medication use. 
 
2.5.2.3 Homocysteine and Type 2 Diabetes 
 
Diabetes is a chronic metabolic disease characterised by hyperglycaemia or high 
blood sugars due to failure of the body to either produce or respond to insulin.  Type 1 
diabetes (T1DM) or insulin-dependent diabetes is generally caused by autoimmune 
destruction of -cells in the pancreas responsible for insulin production. In Type 2 
diabetes (T2DM) or noninsulin-dependent diabetes, the most common form of diabetes, 
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the cells become less sensitive to insulin, and as a result, glucose cannot enter the cells 
and blood glucose rises (Truswell, 2012) .The prevalence of diabetes worldwide (the 
majority being T2DM) is estimated to be 422 million people as of 2014 (World Health 
Organisation, 2018b), with an estimated 250,000 New Zealanders having diabetes in 
2018 (Ministry of Health, 2019c). 
The major cause of T2DM is not clear but there are multiple known risk factors 
for developing T2DM such as being overweight or obese, having a family history of 
diabetes, being age 45 years or older, having high blood pressure, a history of stroke or 
heart disease and having depression (National Institutes of Diabetes and Kidney 
Diseases, 2016). Furthermore, hyperhomocysteinemia, through its harmful metabolic 
effects, may contribute to the pathogenesis of T2DM. Both in vivo and in vitro studies 
have shown that homocysteine has a damaging effect on endothelial function, increases 
systemic inflammation and promotes oxidative stress - all of which, may play a role in 
the development of T2DM (Hofmann et al., 2001; Stamler et al., 2001; Weiss et al., 
2003). 
Despite the plausible implication of homocysteine in the development of 
diabetes, observational studies investigating the association between homocysteine 
levels and T2DM have shown conflicting results. For example, several studies found 
lower (Mazza, Bossone, Mazza, & Distante, 2005; Platt et al., 2017; Yu et al., 2018) 
homocysteine levels in participants with diabetes when compared with healthy controls 
while others found similar or higher homocysteine levels in those with diabetes 
(Ndrepepa et al., 2008; Wang et al., 2015).  
Only two randomised controlled trials, The Women’s Antioxidant and Folic 
Acid Cardiovascular study (WAFACS) and the China Stroke Primary Prevention Trial 
(CSPPT) have investigated the homocysteine-lowering effect of folate with or without 
vitamin B6 and vitamin B12 on the risk of new onset diabetes (Qin et al., 2016; Song, 
Cook, Albert, Van Denburgh, & Manson, 2009). Both trials showed no effect of the 
homocysteine-lowering intervention on the risk of new-onset diabetes among the study 
population. However, in a subgroup analysis of WAFACS, a benefit was seen in the 
intervention group (2.5mg/d folic acid, 50mg/d vitamin B6 and 1mg/d vitamin B12) 
compared to placebo among participants who had a family history of diabetes [RR 
0.77, 95% CI (0.60- 0.99)] (Song et al., 2009). This higher risk tendency was also 
shown in a post hoc analysis of the CSPPT (Qin et al., 2016). Furthermore, in this latter 
study, a beneficial effect was observed in the intervention group for new-onset diabetes 
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or new-onset fasting glucose  7.0 mmol/L where participants had a BMI  30 kg/m2 vs 
BMI < 25 kg/m2. These studies suggest that homocysteine lowering treatment could be 
beneficial in certain population group in the prevention of onset of diabetes but further 
RCT’s are needed. 
2.6 Conclusion  
Maintaining good health in the growing ageing population is of public health 
benefit. Malnutrition, common in older adults and particularly in those living in RACF, 
is a modifiable risk factor in the development of chronic diseases. Improving the 
nutritional status of older adults may improve their quality of life and decrease 
morbidity and delay mortality in this population. 
The prevalence of B-vitamin deficiencies among older adults vary widely across 
studies. Data on biochemical B-vitamin status of older adults living in RACF globally 
are limited and there are no data available from New Zealand. The lack of consensus on 
which biomarkers and cut-off values best define deficient and marginal status together 
with differences in assay methodology contribute to the variation in findings. As a 
result, developing safe and effective guidelines to improve nutritional status in older 
adults in RACF to prevent or delay chronic diseases is challenging.  
Folate, vitamin B12, vitamin B6 and riboflavin play a major role in one-carbon 
metabolism. Suboptimal B-vitamin status results in an increase in homocysteine, which 
has been associated with multiple diseases of the ageing such as stroke, depression and 
diabetes. Homocysteine-lowering trials with folate with or without vitamin B12 and 
vitamin B6 are non-conclusive. Selective groups of participants might benefit more 
than others from supplementation interventions. 
Determining the biochemical B-vitamin status in aged care facility residents in 
New Zealand will contribute much needed baseline data that is required for planning 
and implementation of optimal nutritional strategies targeted at preventing or delaying 
the onset of age-related declines and disease outcomes. 
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3. Subjects and methods 
3.1 Study design, setting and participants 
The New Zealand Nutrition and Ageing Project (NZ-NAPS) was a nationwide 
cross-sectional study with two phases of data collection in 2014; February to April and 
July to September. Twenty RACF were selected from two national RACF websites 
with consideration to geographic distribution and population residency to allow 
sufficient recruitment of approximately 20 residents from each facility. Sixteen facility 
managers agreed to participate (Appendix A). Trained data collectors provided 
information pamphlets and posters (Appendix C, D and E) to each RACF and supplied 
further explanation of the study to interested residents. Rest home staff helped identify 
residents who met the inclusion criteria. 
To participate, residents had to be over 65 years of age and in residential care 
for more than 12 weeks. The latter was to ensure their present nutritional status was not 
confounded by their nutritional status prior to admission. Older adults in dementia units 
and residents who were fully dependant for all activities of daily living were excluded. 
Informed consent was obtained from all participants (Appendix F). If a participant 
could not fully understand the informed consent information due to cognitive decline, 
consent was obtained from a family member or legal guardian (Appendix G). The study 
was approved by the University of Otago Human Ethics (Health) Committee (H13/118) 
(Appendix H) and is registered with the Australia New Zealand Clinical Trials Registry 
(ACTRN 12617001575325) (Appendix I).  
3.2 Demographics and Health Status  
Demographic data (age, sex, ethnicity, length of RACF stay) and medical 
history of cerebrovascular accident (CVA) or transient ischemic attack (TIA), 
hypertension and diabetes as well as usual prescribed medication and vitamin and 
mineral supplements was gathered from medical records (Appendix J). Missing 
information was collected from participants, family or staff. Smoking status was noted 
as current smoker or no smoker. 
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3.3 Geriatric depression scale  
To evaluate the presence of depression, participants were asked to complete the 
Geriatric Depression Scale -Short Form (GDS-SF), a simple and valid screening tool 
for depression in the elderly (Appendix N). The GDS-SF consists of 15 questions about 
wellbeing and mood. Every “no” answer scored one point and a total score greater than 
5 was indicative of depression (Yesavage & Sheikh, 1986). 
  3.4 Malnutrition risk 
The risk of malnutrition was assessed using the Mini Nutritional Assessment 
Short-Form (MNA-SF), a valid screening tool in the geriatric population (Appendix M) 
(Kaiser et al., 2009). The MNA-SF consists of six questions which incorporate reduced 
food intake and unintentional weight loss over the last three months, mobility, 
psychological stress or acute disease, presence of dementia or depression and current 
BMI (Kaiser et al., 2009). This screening tool was completed using information from 
medical records, participants and/or caregivers. Participants were classified as 
malnourished (score of 0-7), at risk of malnutrition (score of 8-11) or normal nutritional 
status (score of 12-14) (Nestlé Nutrition Institute, 2013).  
  3.5 Hand grip strength 
Hand grip strength was measured with a digital dynamometer (JAMAR  
PLUS + Model J00105 Hydraulic Hand Dynamometer, Rolyon, IL USA) using a 
standardised protocol (Roberts et al., 2011). Participants were seated in a chair with 
armrests, wrists over the edge of the armrests with thumbs up, the base of the 
dynamometer supported by the research assistant. The participant was encouraged to 
squeeze the dynamometer as powerfully as they could. This measurement was repeated 
three times on alternating sides assuring a rest of at least a minute in between 
(Appendix K). The highest of the six measurements was used in calculating the frailty 
score. 
  3.6 Frailty  
Frailty scores were established using the Survey of Health, Ageing and 
Retirement in Europe Frailty Instrument (SHARE-FI) (Romero-Ortuno, Walsh, Lawlor, 
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& Kenny, 2010). The SHARE-FI is a simple validated instrument (Romero-Ortuno et al., 
2010) that can predict mortality similarly to a frailty index based on comprehensive 
geriatric assessment (Romero-Ortuno, 2013). SHARE-FI is based on five frailty items. 
Participants were assigned a score for each of five variables. The first four variables: 
exhaustion, change in appetite, low activity and walking difficulty were scored based on 
participant responses to previously validated questions (Figure 3.3). Carers were asked 
to answer any questions that participants could not, based on their knowledge of the 
resident. The fifth variable, weakness, was measured by handgrip strength as described 
above. The Share-FI calculator was used to give participants a score, thereafter they were 
categorised as non-frail, pre-frail or frail as per the sex-specific cut-offs (Romero-Ortuno 












(Romero-Ortuno et al., 2010).  
  3.7 Anthropometric measurements 
Anthropometric measurements were carried out applying standardised 
procedures (Appendix L). Body weight of participants in light clothes and without 
shoes was measured to the nearest 0.1 kg using a calibrated electronic Seca 813 
weighing scale (Seca Corporation, Hamburg). Participants who could not stand on the 
scales unsupported were weighed on calibrated rest-home seated scales. Height was 
estimated from ulna length measurements, measured with a Lufkin Thinline 
anthropometry tape (Apex Tool Group, Baltimore) to the nearest 0.1 cm. This 
measurement was repeated in triplicate on a seated participant’s non-dominant side and 
Self-reported variables for SHARE-FI  
Exhaustion: coded as 1 for a positive response to the following statement – “In the last month I felt 
everything I did was an effort”. A positive answer was coded as 1, and no coded as 0. 
Change in appetite: participants were asked to respond to the following question – “In the past 
THREE MONTHS, has your food intake declined?” A positive answer was then clarified by asking 
“Have you been eating poorly because of a decreased appetite?” A positive response was coded as 
1 and a negative response as 0.  
Low activity: “How often do you engage in activities that require a low or moderate level of energy, 
such as going on a walk?” Responses were coded as ordinal: 1 = more than once a week, 2= once a 
week, 3= one to three times a month and 4 = hardly ever or never. 
Walking difficulty (slowness): “Because of a physical problem, do you have difficulty (expected to 
last more than 3 months) walking 100 metres or climbing one flight of stairs without resting?” 
Coded as 1 if either difficulty was encountered or 0 if two negative responses were received.  
Figure 3.3 Measurement of self-reported variables for frailty assessment 
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an average of these three measurements was calculated. Ulna length was converted to 
height using conversion charts (Todorovic, Russell, & Marinos, 2003). Body Mass 
Index (BMI) values were calculated as weight (kg) divided by height (m2). Cut-off 
values used to classify participants were: < 20 kg/m2 for underweight; 20-24.99 kg/m2 
for healthy weight; 25-29.99 kg/m2 for overweight and  30 kg/m2 for obese. 
  3.8 Blood samples 
Fasting peripheral venous blood samples were collected from 263 participants 
in a sitting position by trained phlebotomists (Appendix O). Samples were drawn into 
EDTA, heparin, trace element free and serum vacutainers (Becton Dickinson, Franklin 
Lakes, NJ) and were immediately chilled on ice. These were then transported chilled to 
a local accredited laboratory where complete blood count was measured. Whole blood, 
serum and plasma samples in phase one where processed within three hours of 
collection and transferred to cryovials to be stored at -70 degrees Celsius at the 
Department of Human Nutrition, University of Otago. During the second phase all but 
blood collections from two RACF (Wellington) were processed and centrifuged within 
five hours of collection. Processing of the blood samples from the two Wellington 
RACF was delayed until the next day, but where kept chilled during the delay.  
Serum vitamin B12 was measured by automated ECLIA (Elecsys 2010®; Roche 
Diagnostics GmbH, Mannheim, Germany). The means (SD) and CV for the two 
manufacturer-provided controls (Elecsys Preci-Control Varia 1 and 2) which were 
analysed with each reagent kit were 472.37 (18.04) pg/ml; 3.8% and 1100.64 (40.74) 
pg/ml; 3.7%, respectively, and were within the range of the results provided by the 
manufacturer. Pooled serum inter-assay CV was 7.3% (n = 7). Vitamin B12 < 148 pmol/L 
was considered deficient, 148-221 pmol/L marginal and > 221 pmol/L as adequate status. 
In addition, those participants with a value above 650 pmol/L were classified as high 
(Canterbury Health Laboratories, 2013). Participants with a value above the highest 
detectable assay value (2000 pmol/L, n=8) were given a value of 2001 pmol/L.  
Serum folate was measured by microbiologic assay using the method of 
O’Broin and Kelleher (O'Broin & Kelleher, 1992) and Molloy and Scott (Molloy & 
Scott, 1997). Lactobacillus rhamnosus (ATCC 7469) was used as the microorganism 
and 5-methyltetrehydrofolate as the calibrator. Each plate included a low, medium and 
high pooled quality serum control expressed as mean (± 2 standard deviations); low 
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15.0 (3.8) nmol/L; medium 26.3 (5.2) nmol/l; high 45.5 (11.5) nmol/L. Serum folate < 
6.8 nmol/L was considered deficient. (University of Otago; Ministry of Health, 2011). 
Participants with a serum folate value above 45.3 nmol/L were classified as high 
(Pfeiffer, Caudill, Gunter, Osterloh, & Sampson, 2005). 
Riboflavin and vitamin B6 status was assessed using stimulation tests of 
erythrocyte glutathione reductase (EGR, EC 1.6.4.2.) by FAD (riboflavin) and 
erythrocyte aspartate aminotransferase (EAST, EC 2.6.1.1.) by PLP (pyridoxal-5-
phosphate) in washed red blood cells (vitamin B6) (Cobas Mira; Roche Diagnostics 
GmbH) (Vuilleumier, Keller, & Keck, 1990). An activation coefficient for EGR (EGR-
AC) and EAST (EAST-AC) was calculated as the ratio of the activity of the enzyme 
before and after addition of FAD and PLP respectively (ac = stimulated/ non-
stimulated). EGR-AC < 1.2 is regarded as sufficient riboflavin status, 1.2-1.4 as 
marginal and > 1.4 as deficient (Mc Cormick D.B. & Greene H.L., 1994). EAST-AC < 
1.7 is considered sufficient vitamin B6 status, 1.7-1.85 marginal and > 1.85  is regarded 
as deficient (Sauberlich, 1999). 
Serum creatinine was measured using Creatinine Jaffé Gen.2 kinetic 
colorimetric assay (Cobas c311®; Roche Diagnostics GmbH). A high and low control 
provided by the manufacturer (PCCM1 and PCCM2) were analysed daily. The means 
of the two controls were 96 (SD 1·0) μmol/l (CV 1·0 %) and 368 (SD 5·8) μmol/l (CV 
1·6 %), respectively. Serum creatinine, age and sex were entered in an online calculator 
from the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) to calculate 
the estimated Glomerular Filtration Rate (eGFR), an indicator of renal function (Kidney 
Health Australia, 2019). 
Serum high sensitivity C-reactive protein (CRP) and α-1-acid glycoprotein 
(AGP) were measured by automated immunoturbidimetric assay (Cobas c311; Roche 
Diagnostics GmbH). Quality tests were performed using the manufacturer’s control 
material, PreciControl ClinChem Multi (PCCM) 1 and 2 (Roche Diagnostics GmbH). 
All results were within the range stated by the manufacturer. Values for CRP > 5 mg/L 
and AGP > 1g/L were considered elevated.  
Serum interleukin-6 (IL-6) was analysed using an electrochemiluminescence 
immunoassay (Elecsys 2010; Roche Diagnostics GmbH). Precision and accuracy were 
checked daily and with each new reagent kit using manufacturer controls, Multimarkers 
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1 and 2 (Roche Diagnostics GmbH). Values below the detectable limit of 1.5 pg/mL 
were given a value of 1.4 pg/mL. 
Plasma homocysteine, free choline and betaine were measured by isotope 
dilution-liquid chromatography-tandem mass spectrometry (ID-LC-MS/MS) on an API 
3200 instrument (Applied Biosystems, Foster City, CA, USA) based on the method 
developed by Rosalind Stamm (Stamm, 2016). Hyperhomocysteinemia was defined as 
homocysteine above 15 mol/L, 15-30 mol/L is considerate mild and 30-100 mol/L 
moderate hyperhomocysteinemia (Moretti & Caruso). Homocysteine concentration  
>13 mol/L was also presented as reported in some studies (Allen et al., 2018). 
  3.9 Sample size  
To detect a prevalence of hyperhomocysteinemia to a 95% precision level of +/- 
6%, a sample size of 267 was required. The study sample for the purpose of this thesis 
was restricted to pa rticipants with complete data on homocysteine and select one 
carbon nutrients (n 263). 
  3.10 Statistical methods 
Statistical analyses were performed using Stata statistical software package 
(version 15.0; StataCorp). P-values  0.05 were regarded as statistically significant. 
  Descriptive statistics were calculated and presented as n (%) or geometric mean 
and 95% confidence interval (CI). Biochemical indices were expressed as mean  SD, 
median and range. T-test for differences between means of homocysteine 
concentrations with and without time-delay on blood processing was performed. The 
distribution of all biochemical markers was visually checked for normality. The 
concentration of plasma homocysteine, serum folate, vitamin B12, riboflavin, choline, 
betaine and inflammatory markers showed a positively skewed distribution therefore all 
analyses were done by using natural logarithmic transformation to improve the 
normality of the distribution. Linear regression was used to analyse differences in 
homocysteine concentration between the different nutritional status. Pearson correlation 
coefficients were calculated to evaluate the relationship between homocysteine folate, 
vitamin B12, vitamin B6, riboflavin, betaine and choline.  
To determine predictors of plasma homocysteine, B-vitamins (serum folate, vitamin 
B12, vitamin B6, riboflavin) and one-carbon metabolites (choline and betaine), as well 
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as renal function, inflammatory parameters, metformin, ace inhibitors and diuretics 
were analysed. Initially each predictor was assessed in a linear mixed effects regression 
model that was adjusted for age and sex. Subsequently, all nutrients and variables with 
a significant p-value from the analyses were included in a fully adjusted model. All 
models included rest home cluster as random effect. To allow comparison of strength of 
association with homocysteine between biomarkers, all of the biochemical indices were 
standardised (i.e., the difference between each measurement and the mean divided by 
the SD) therefore the standardised variables have a mean of zero and a SD of one. 
Thus, values in the regression model are interpretable as a proportion of a SD change in 
homocysteine for each SD change in the independent variable. A sensitivity analysis 
was performed excluding those blood analyses with a time-delay in processing (<3 
hours vs all). To assess differences in plasma homocysteine between participants with 
and without health conditions linear mixed regression model was adjusted for relevant 
confounders.  
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4. Results 
Of the 309 enrolled participants, 16 did not have blood samples collected and a 
further 30 were missing homocysteine or select one carbon nutrient analysis. Thus, 263 
(85%) participants had data available for the association analysis.  
Participant characteristics and health status are presented in Table 4.3. The median age 
was 85 years (range 65 to 107 years) and the average length of residency in the aged care 
facility was 32 months (range 2 months to 13 years). The majority of participants were 
women and of New Zealand European ethnicity. Half of participants were classified as either 
overweight or obese while 7% were underweight. The prevalence of malnutrition was less 
than 10%, while the majority of participants were determined to be frail or pre-frail. Over 
half of the sample population had hypertension, one-quarter had a history of CVA/TIA, one-
quarter exhibited diabetes, and almost half of participants had impaired renal function (eGFR 
< 60 ml/min/1.73m2).  
Table 4.4 shows the nutritional and inflammatory status of the sample population. 
Serum folate levels ranged from 1.9 to 264.5 nmol/L, and vitamin B12 from 141.2 to 2001 
pmol/L. Riboflavin and vitamin B6 status as measured by EGR-AC and EAST-AC ranged 
from 0.9 to 1.4 units and 0.7 to 3 units, respectively. The prevalence of inflammation 
determined by elevated IL-6 (greater than age and sex-specific median) was present in almost 
all (99%) participants. In addition, high circulating levels of CRP (> 5 mg/L) and AGP (> 1 
g/L) were shown in 35% and 28% of participants, respectively.  
Almost 10% of participants exhibited folate deficiency (< 6.8 nmol/L) but only one 
participant had a vitamin B12 concentration < 148 pmol/L, considered deficient (Table 4.5). 
In contrast, a number of participants (11.4%; n 30) had a high vitamin B12 level > 650 
pmol/L. After applying a sequential algorithm using both serum vitamin B12 and 
homocysteine as biomarkers for vitamin B12 deficiency (Allen et al., 2018), 11.8% (n 31) of 
participants were classified vitamin B12 indeterminant (vitamin B12 ranging between 148 
and 250 pmol/L) and 9.5% (n 25) also had plasma homocysteine > 15 mol/L, resulting in a 
classification of vitamin B12 deficiency of 9.9%. There was no evidence of riboflavin 
deficiency among the sample population. In contrast, vitamin B6 deficiency was present in 
37% of the participants (Table 4.5). The prevalence of deficiency or marginal B vitamin 
status by age group is depicted in Figure 4.4. There were no differences in B-vitamin status 
among age groups with the exception of vitamin B12 where a significantly lower prevalence 
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of marginal vitamin B12 status was present in participants aged 75-85 years compared to the 
> 85 years group (1.4% vs 11.7%, p= 0.006). 
With regards to the prevalence of high B-vitamin status, 11% (n 29) of participants 
had high circulating levels of serum folate (> 45.3 nmol/L). Of those, 31% (n 9) were taking 
folic acid supplements (ranging from 5 mg/week to 5 mg/day). Moreover, 11% (n  30) of 
participants were taking vitamin B12 supplements – of which, 57% (n 17) had high vitamin 
B12 values (serum vitamin B12 > 650 pmol/L), none were classified vitamin B12 deficient, 
3% (n 1) had a marginal vitamin B12 status, and the remainder had adequate status.  
Mild hyperhomocysteinemia (HHcy), (15-30 mol/L), was present in almost two-thirds 
of participants while few participants [4% (95% CI 2-7)] exhibited moderate HHcy (30-100 
mol/L) (Table 4.5). Of those participants with hyperhomocysteinemia, 7% were in the 65-
75 years range, 24% in the 75-85 years range and 69% > 85 years of age. Plasma 
homocysteine concentrations were significantly higher among the folate deficient participants 
compared to participants with adequate folate status (Table 4.3) yet did not differ among 
participants exhibiting deficient, marginal and adequate vitamin B12, riboflavin and vitamin 
B6 status. No significant difference was found in homocysteine between RACF with and 
without time-delay on blood processing. 
Correlation coefficients (Pearson’s r) (Table 4.6) between natural log homocysteine 
and serum folate, plasma vitamin B12 and betaine indicated an inverse relationship, albeit 
weak. Furthermore, there was a weak positive correlation between plasma homocysteine 
concentration and plasma free choline. Not surprisingly, plasma choline and betaine had a 
moderate positive correlation.  
Table 4.7 shows the associations between age- and sex-adjusted homocysteine, folate, 
vitamin B12, free choline, betaine, renal function, IL-6 and diuretics. After multivariate 
adjustment, serum folate, plasma vitamin B12 and betaine were inversely associated with 
homocysteine and choline was positively associated with homocysteine. For every SD rise in 
folate, there was a 9% lowering of homocysteine, whereas for every SD increase of vitamin 
B12 and betaine, there was an 8% decline in homocysteine. Furthermore, for every SD rise in 
choline there was a 10% increase in homocysteine. Estimated glomerular filtration rate and 
use of any diuretics also remained significantly associated with homocysteine, albeit slightly 
attenuated. The inflammatory marker, IL-6 was significantly related with 
hyperhomocysteinemia. Neither vitamin B6 nor riboflavin were associated with 
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homocysteine. Sensitivity analyses showed that these associations were robust to possible 
effects of time-delays on some of the blood processing. 
Mean plasma homocysteine values by existing health condition are shown in Table 4.8. 
There was no significant mean difference in homocysteine in participants with or without 
diabetes, depression or a history of CVA /TIA. 
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Table 4.3 Demographic and health characteristics of study participants, n 263 
 n n (%)1 
Age, (years) GM (95% CI) 263 84.9 (84.0, 85.9) 
Female  173 (65.8) 
Body mass index, (kg/m2) GM (95% CI) 258 25.1 (24.5, 25.7) 
Obese2 258 48 (18.6) 
Current smokers 254 10 (3.9) 
Polypharmacy ( 5 meds/day)  262 187 (71.4) 
Malnutrition screening3 
Normal nutritional status 




















Hypertension  258 158 (61.2) 
Diabetes  258 64 (24.8) 
CVA/TIA  258 63 (24.4) 
eGFR (ml/min/1.73m2), GM (95% CI) 261 57.9 (55.4, 60.5) 
1 Values are number and proportion (%) unless otherwise specified. 
2 Classified as BMI 30  
3 Coded by Mini Nutritional Assessment Short Form (MNA-SF) (Nestlé Nutrition Institute, 2013) 
4 Coded by the Survey of Health, Ageing and Retirement in Europe Frailty Instrument (Share-Fi)(Romero-
Ortuno et al., 2010) 
5Coded by the Geriatric Depression Scale Short Form (Yesavage & Sheikh, 1986) 
Abbreviations: CI, confidence interval; CRP, C reactive protein; IL-6 Interleukine-6; AGP, alpha-1-acid 
glycoprotein; GM, geometric mean; CVA, cerebrovascular accident; TIA, transient ischemic attack; eGFR, 
estimated glomerular filtration rate. 
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Table 4.4 Biochemical nutritional and inflammatory indices of study participants, n 263 
 n Mean (SD) Median Range 
Plasma homocysteine (mol/L) 263 17.9 (6.1) 17.2 7.1-46 
Serum folate (nmol/L) 259 25.6 (31.3) 15.2 1.9-264.5 
     
Serum vitamin B12 (pmol/L) 263 493.0 (370.6) 377.1 141.2-2001 
     
EGR-AC (Riboflavin) 241 1.0 (0.1) 1.0 0.9-1.4 
     
EAST-AC (Vitamin B6) 241 1.7 (0.3) 1.8 0.7-3.0 
Plasma betaine (mol/L) 263 41.8 (15.1) 39.7 16.3-110 
Plasma free choline (mol/L) 
 
263 13 (3.5) 12.3 6.1-31.4 
Inflammatory markers  
Serum CRP (mg/L) 
Serum IL-6 (pg/ml) 


















Abbreviations: EGR-AC, Erythrocyte glutathione reductase activation coefficient; EAST-AC Erythrocyte 
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Table 4.5 Age- and sex-specific geometric mean homocysteine concentrations and estimated 
prevalence of folate, vitamin B12, riboflavin and vitamin B6 status of study participants 
 
n %  





(95% CI)4 p-value 
Plasma homocysteine (mol/L)      
> 13 203 77.2     
15-30 166 63.1     
> 30  10 3.8     
Serum folate (nmol/L) 
      
< 6.81  23 8.9  20.9 (18.2-23.9) 27 (11, 45) 0.001 
 6.83 236 91.1  16.6 (15.9-17.3) Reference  
Serum vitamin B12 (pmol/L)      
< 1481  1 0.4 14.4   
148-2212 20 7.6  19.8 (17.1-22.9) 8 (-7, 25) 0.308 
➢ > 2213  242 92.0  16.7 (16-17.4) Reference  
EGR-AC (Riboflavin)      
➢ > 1.41 0 0    
1.2-1.42 10 4.1  17.7 (14.6-21.6) -4 (-22, 17) 0.663 
< 1.23  231 95.9    16.8 (16.1-17.5) Reference  
EAST-AC (Vitamin B6)      
➢ > 1.851  88 36.5  16.9 (15.7-18.1) 2 (-7, 12) 0.636 
1.7-1.852 59 24.5  16.9 (15.6-18.3) 2 (-9, 13) 0.762 
< 1.73 94 39.0  16.7 (15.5-18.0) Reference  
1Deficient status; 2 marginal status; 3 sufficient status, 4 Mean homocysteine difference is adjusted for age and 
sex. 
Abbreviations: EGR-AC, Erythrocyte glutathione reductase activation coefficient; EAST-AC, Erythrocyte 
aspartic acid transaminase activation coefficient; GM, geometric mean  
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Figure 4.4 Prevalence of deficient and marginal B-vitamin status category by age groups:  
65-74 years, 75-85 years and greater than 85 years compared to all participants 
Deficient serum folate < 6.8 nmol/L; marginal serum vitamin B12: 148-221pmol/L, marginal 














Deficient folate Marginal vitamin
B12
Marginal riboflavin   Deficient vitamin
B6











65-74 years 75-85 years >85 years all
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Abbreviations: EGR-AC, Erythrocyte glutathione reductase activity coefficient; EAST-AC, Erythrocyte aspartic acid transaminase activity coefficient 
 
 Plasma  
homocysteine 








Serum folate -0.377      
Serum vitamin B12 -0.211 0.109     
EAST-AC vitamin B6 0.107 -0.187 -0.043    
EGR-AC riboflavin -0.023 -0.065 -0.051 0.219   
Plasma betaine -0.252 0.367 0.081 -0.181 -0.002  
Plasma free choline 0.252 0.166 0.090 -0.236 -0.107 0.412 
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Table 4.7 Associations of nutritional and non-nutritional biomarkers and age- and sex-
specific homocysteine  
1 Biochemical indices were standardised 
2Adjusted for age, sex, rest home cluster, eGFR, serum folate, vitamin B6, vitamin B12, riboflavin, plasma 
choline, betaine, IL-6, any diuretics 
Abbreviations : eGFR, estimated glomerular filtration rate; CRP, C reactive protein; IL-6 Interleukine-6; AGP, 
alpha-1-acid glycoprotein 
 Plasma homocysteine 
Variable1 Age and sex   
adjusted 




% (95% CI)  % (95% CI)  
Serum folate -10 (-14,-7) <0.001 -9 (-13,-6) <0.001 
Serum vitamin B12 -7 (-10,-3) <0.001 -8 (-11,-5) <0.001 
Riboflavin 0 (-4,4) 0.922 0 (-3,3) 0.869 
Vitamin B6  3 (-1,7) 0.212 3 (0,7) 0.076 
Plasma free choline 7 (3,11) <0.001 10 (5,14) <0.001 
Plasma betaine -8 (-12,-5) <0.001 -8 (-11,-4) <0.001 
eGFR -13 (-16,-9) <0.001 -9 (-12,-5) <0.001 
CRP 1 (-2,5) 0.503 - - 
IL-6 4 (0,8) 0.029 4 (0,7) 0.023 
AGP 2 (-2,5) 0.406 - - 
Metformin (n=28) 3 (-14,10) 0.679 - - 
Any diuretics (n=115) 17 (9,26) <0.001 13 (6,20) <0.001 
Loop diuretics (n=97) 14 (6,23) 0.001 - - 
Ace inhibitors (n=38) 1 (-9,13) 0.849 - - 
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Table 4.8 Mean homocysteine concentration of study participants with and without diabetes, 
stroke and depression  
 
 
1Adjusted for rest home  
2 Adjusted for age, sex, BMI, eGFR, any diuretics, smoking and rest home 
3Adjusted for age, sex, BMI, eGFR, any diuretics, smoking, rest home, vitamin B12, folate, choline, betaine,  
 IL-6, any diuretics  
Abbreviations: CVA, cerebrovascular accident; TIA, transient ischemic; IL-6 Interleukine-6; eGFR, estimated 
glomerular filtration rate  
 With condition Without condition Mean % difference 
(95% CI) 









Model 11 Model 22 Model 33 
Diabetes 
 
64 18.5 (6.5) 194 17.6 (6.1) 2 (-7,12) 1 (-7,10) 2 (-6,9) 
CVA/TIA 63 17.8 (6.2) 195 17.9 (6.2) 0 (-8,10) -2 (-10,6) -3 (-10,4) 
Depression 
 
74 17.2 (5.4) 168 18.2 (6.4) -5 (-13,4) -3 (-10,4) -1 (-8,6) 
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5. Discussion 
To our knowledge, this is the first study to report data on the status of multiple 
B-vitamins together with one carbon metabolites in older adults in RACFs in New 
Zealand. The prevalence of folate, vitamin B12 and riboflavin deficiency among the 
study population was low while vitamin B6 deficiency was high – however, caution is 
warranted as the analytical method employed to measure vitamin B6 status may have 
overestimated the prevalence of deficiency (Huang, Chen, Evans, Mitchell, & Shultz, 
1998; Ueland et al., 2015). Nonetheless, despite mostly optimal B-vitamin status, 
homocysteine was elevated, and inversely associated with folate, vitamin B12 and 
betaine, and positively associated with choline. These associations remained robust 
even after adjustments for potential confounders such as age, sex, renal function, 
inflammation and diuretics. Although many studies have indicated an association 
between select disease outcomes and homocysteine (Almeida et al., 2008; Wang et al., 
2015; Zhang et al., 2009), concentration of such in the present study did not differ 
among participants with or without diabetes, stroke or depression.  
Prevalence of B-vitamin Deficiencies 
Despite the low prevalence of folate deficiency (9%) in the present study, our 
findings were higher than those reported in the most recent national Adult Nutrition 
Survey 2008-09 in community-dwelling adults 70 years of age and older ( 2%) 
(University of Otago & Ministry of Health, 2011) and the UK National Diet and 
Nutrition Survey in older adults (6%; 2014/2015 to 2015/2016) (Public Health England, 
2018). Other surveys in NZ among community-dwelling older adults such as the 
LiLACS study – a cohort of participants 80 years and older – have also reported a 
lower prevalence of folate deficiency (only 2%) (University of Otago & Ministry of 
Health, 2011) consistent with several smaller studies in Dunedin (de Jong et al., 2003) 
and Christchurch (Hanger et al., 1991) (4% and 1% , respectively). It is important to 
note that NZ and the UK have a voluntary folic acid food fortification policy 
(Department of Health and Social Care, 2019; Ministry of Primary Industries, 2018) 
while countries like the USA have mandatory folic acid fortification of cereal grain 
products (Department of Health and Human Services Food and Drug Administration, 
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1996), with negligible reports of folate deficiency among older US adults aged 60 years 
and over (Pfeiffer et al., 2012; Pfeiffer et al., 2019).  
Nevertheless, older adults residing in aged care are at higher risk of malnutrition 
compared to community-dwelling residents (Cereda et al., 2016; Verbrugghe et al., 
2013; Wham et al., 2017) and subsequently, at an increased risk of micronutrient 
deficiencies. As such, our findings in a RACF-setting are closely aligned with the 
higher prevalence of folate deficiency (12%) reported among institutionalised older 
adults in Hong Kong (Wong et al., 2015). In the latter study, males were at a 
significantly higher risk of folate deficiency (16.2%) compared to females (8.5%) 
(Wong et al., 2015) – a finding which was not found in our study (data not shown). A 
number of other studies have investigated folate status among older adults in RACF 
however, biomarkers and cut-off values vary making comparisons difficult (Brito 
Noronha et al., 2015; Gonzalez-Gross et al., 2007; Huerta et al., 2004; Paulionis et al., 
2005). Indeed, the comparison of all biochemical results in the present study is 
challenging as consensus is lacking regarding the types of biomarkers, assays and cut-
offs used to define optimal status in this lifecycle group. For example, The Irish 
Longitudinal Study on Ageing (TILDA) reported a higher prevalence of folate 
deficiency of 20% among free living older adults using a higher cut-off for plasma 
folate (< 10 nmol/L) compared to the present study (< 6.8 nmol/L) (Laird et al., 2018). 
If we applied the same higher cut-off value, the prevalence of folate deficiency in our 
study population would be similar (26% vs 9%).  
With regards to high folate status, a small proportion of our population had 
serum folate concentrations above the normal reference range (> 45.3 nmol/L). In 
NHANES III and NHANES 1999-2000, 8% and 38% of older adults respectively 
exhibited serum folate concentrations > 45.3 nmol/L (Pfeiffer et al., 2005). The US 
Institute of Medicine has set an upper level of folate intake for adults because of the 
concern that excessive folic acid intake can mask anaemia in older adults who are 
vitamin B12 deficient, thereby exacerbating the neurological consequences of vitamin 
B12 deficiency (Institute of Medicine Food and Nutrition Board, 1998). However, the 
true concentration of serum folate that should be regarded as excessively high is 
unknown.  
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The prevalence of vitamin B12 deficiency was less of a concern in the present 
study. Only one participant was considered vitamin B12 deficient (serum vitamin B12 
< 148 pmol/L) and less than 10% exhibited marginal status (serum vitamin B12 148-
221 pmol/L). These findings are in contrast to the prevalence of deficient vitamin B12 
status (serum vitamin B12 < 148 pmol/L) in community-dwelling participants in 
various national surveys (4-20%) (Allen et al., 2018; Clarke et al., 2004; Green et al., 
2017; MacFarlane et al., 2011; McLean et al., 2008), and observational studies of 
community-dwelling participants (7-24.8 %) (de Jong et al., 2003; Jungert & 
Neuhäuser-Berthold, 2019; Mendonça et al., 2016; Pillay et al., 2018; van Asselt et al., 
1998) and RACF residents (5-34.9%) (Gharaibeh et al., 2010; Gonzalez-Gross et al., 
2007; Mirkazemi et al., 2012; Paulionis et al., 2005; Pfisterer et al., 2016; Whitfield et 
al., 2018; Wong et al., 2015). However, in line with previous studies (Conzade et al., 
2017; Risch et al., 2015), the prevalence of marginal vitamin B12 status increased with 
age ranging from less than 2% deficiency in those aged 65-85 years to 12% for those > 
85 years group. The only participant with vitamin B12 deficiency was 90 years of age. 
Only 30 participants were taking supplements containing vitamin B12 , with over half 
of these participants having a vitamin B12 concentration above 650 pmol/L. No upper 
level of intake has been set for vitamin B12 as there are insufficient data available . 
Furthermore, no known adverse effects have been documented with excess vitamin B12 
intake from food or supplements in healthy people (Ministry of Health, 2019b). 
 
Inadequate vitamin B12 intake and malabsorption are the main causes of poor  
vitamin B12 status (Allen et al., 2018). Dietary intake in general decreases in older 
adults (Amarya et al., 2015) and malabsorption of vitamin B12 increases with age 
(Green et al., 2017), leading to a higher prevalence of suboptimal vitamin B12 status. 
Assessing vitamin B12 via serum vitamin B12 is commonly used as it is inexpensive 
and readily available, yet the sensitivity and specificity of this biomarker is limited 
(Allen et al., 2018). The use of multiple biomarkers, including homocysteine to define 
vitamin B12 deficiency has recently been recommended (Allen et al., 2018). In doing 
so, the prevalence of vitamin B12 deficiency in the present study increased from 0.4% 
to 9.9%. No study to date has employed this algorithm in the assessment of vitamin 
B12 deficiency in an older population group in RACF. 
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Riboflavin deficiency in the present study was absent, with only 4% of the 
sample population exhibiting even a marginal status. Our findings differ substantially 
from previous studies in both community-dwelling and institutionalised older adults – 
albeit investigations of riboflavin status in older adults are limited and results are 
inconsistent. The Taiwanese Elderly Nutrition and Health Survey of free-living older 
adults reported a low prevalence of riboflavin deficiency (5%) however, the proportion 
of participants with marginal riboflavin status was substantially higher (25%) than the 
present study (Yang et al., 2005). Likewise, the UK NDNS found that 40% of free-
living older adults were considered riboflavin depleted (Public Health England, 2016). 
Among studies in RACF participants, suboptimal riboflavin status of up to 50% have 
been reported in Canada (Whitfield et al., 2018) and France (Essama-Tjani et al., 2000) 
with lower rates of deficiency in Germany (6.2%) (Hahn et al., 2003) and Spain (10%) 
(Lopez-Sobaler et al., 2002) albeit cut-off values varied. 
To date, no studies have reported biochemical vitamin B6 status among older 
adults in New Zealand. In the present study, one-third of participants were classified as 
vitamin B6 deficient, with an additional one-quarter exhibiting marginal status. It is 
important to note that the method employed in the present study to assess vitamin B6 
status (EAST-AC) is best performed on fresh blood samples as EAST activity 
diminishes during frozen storage (Huang et al., 1998; Ueland et al., 2015); our samples 
were analysed using thawed blood stored for approximately 4 years. This procedure 
likely resulted in an overestimation of the prevalence of vitamin B6 deficiency. The 
majority of studies investigating vitamin B6 status of older adults use pyridoxal 5’ 
phosphate (PLP) as a status biomarker, with a cut-off value < 20 nmol/L indicating 
deficiency. As such, the prevalence of vitamin B6 deficiency ranges among free-living 
older adults in the following studies: 22% in the multicentre European study SENECA 
(van der Wielen et al., 1996) and 16% in NHANES 2005-2006 (U.S. Centers for 
Disease Control and Prevention, 2012). In RACF, the reported prevalence of vitamin 
B6 deficiency assessed by PLP varies considerably among countries from < 1% in a 
rest home study in Spain (Gonzalez-Gross et al., 2007), 5% of older adults in long-term 
hospital care in Canada (albeit using a higher cut-off value in the latter study (<30 
nmol/L) (Paulionis et al., 2005) and 50% of older adults residing in nursing homes in 
Norway (Kjeldby et al., 2013).  
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Circulating levels of homocysteine 
Despite the low prevalence of folate and vitamin B12 deficiency, the prevalence 
of hyperhomocysteinemia was high. In the present study, 63% had mild and 4% 
moderate hyperhomocysteinemia. These findings are similar to those previously 
reported in studies among older adults in RACF in Spain (Gonzalez-Gross et al., 2007; 
Huerta et al., 2004), Canada (Paulionis et al., 2005), Japan (Ao et al., 2019) and Jordan 
(Gharaibeh et al., 2010), albeit that the prevalence of folate and vitamin B12  
deficiencies in these studies were higher and cut-off values varied. 
Multiple nutritional (Holm Pål et al., 2005; Holm et al., 2007; Jacques et al., 
2001; Konstantinova et al., 2007; Mahmood, 2014; Miller, 2013; Refsum et al., 2004) 
and non-nutritional predictors (Ham et al., 2014; Refsum et al., 2006; van Guldener, 
2006; Wang et al., 2017; Yao et al., 2017) of homocysteine have been explored in 
previous studies. The findings from the present study confirms the associations between 
fasting plasma homocysteine and folate, vitamin B12, betaine, renal function and use of 
diuretics. Unexpectedly, in this study choline was positively associated with 
homocysteine, however the effect size was small. This result is inconsistent with most 
studies which show either a negative or no association between choline intake and 
plasma total homocysteine (Chiuve et al., 2007; Cho et al., 2006; Lee et al., 2010). 
However, a 12-week controlled feeding study found a similar positive relationship 
between choline intake and plasma homocysteine among healthy Mexican-American 
men with a MTHFR 677TT gene mutation whereas choline intake was not a predictor 
of homocysteine in those with MTHFR 677CC genotype (Caudill et al., 2009). The 
mechanism by which choline interacts with the MTHFR gene is unknown. Because we 
did not determine MTHFR C677T genotype in the present study, we were unable to 
assess the extent to which this condition contributed to the choline-homocysteine 
interrelationship.   
 
Relationship of homocysteine with diabetes, depression and 
stroke 
Multiple studies have shown an association between homocysteine and diabetes 
(Wang et al., 2015), depression (Almeida et al., 2008) and stroke (Zhang et al., 2009). 
In the present study, there was no significant mean difference in homocysteine 
concentration in participants with or without a history of these conditions in the 
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different models applied. To date, randomised supplementation trials examining the 
effect of homocysteine-lowering treatment on the risk of stroke, depression and 
diabetes are nonconclusive. The majority of trials show no overall risk reduction except 
in certain treatment subgroups of the population. For example, a 21% risk reduction for 
stroke was seen among hypertensive patients treated with enalapril and folic acid 0.8 
mg/d compared to those not receiving folic acid (Huo et al., 2015). Furthermore, in a 
study by Hankey et al., participants who were not on antiplatelet treatment prior to 
stroke had a 35% risk reduction of recurrent stroke for those who received B vitamin 
supplementation (2 mg/d folic acid, 25 mg/d vitamin B6 and 0.5 mg /d vitamin B12) 
compared to those receiving placebo (Hankey et al., 2012). In a study of new onset 
diabetes among women, a protective benefit was seen in those with a family history for 
diabetes in the intervention group receiving 2.5 mg/d folic acid, 50 mg/d vitamin B6 
and 1 mg/d vitamin B12 compared to placebo (Song et al., 2009). These findings 
suggest that folic acid supplements with or without vitamin B6 and vitamin B12 may be 
appropriate in select subgroups of the older population. We were unable to examine the 
association between homocysteine and diseases in these select subgroups. 
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Strength and limitations 
The present study had some limitations. Although the sample size was fairly 
large (n 263) and included multiple RACF throughout New Zealand, the study 
population was not representative of the wider RACF population. The exclusion of 
older adults from dementia and full dependency units limits the application of our 
findings to the breadth of RACF settings as these units are associated with poorer 
dietary intake and nutritional status (Volkert et al., 2015). Furthermore, the potential for 
selection bias should be noted as RACF that were willing to participate in this study 
might have been more interested in the nutritional wellbeing of their clients than others 
who declined participation. Lastly, it would have been valuable to have food 
consumption data to better understand the nutritional status of participants, and the 
existing differences among studies. Nevertheless, the examination of multiple 
micronutrients, including choline and betaine, and their interrelationships with 
homocysteine while controlling for known confounders such as certain medications and 




In summary, hyperhomocysteinemia was prevalent in this sample population of 
RACF residents despite the low prevalence of folate, vitamin B12 and riboflavin 
deficiency – albeit vitamin B6 deficiency appeared high. Folate, vitamin B12, betaine 
and choline were independently associated with homocysteine concentration; however, 
no associations were found between homocysteine and disease outcomes such as 
stroke, diabetes and depression. To our knowledge, it is not known whether further 
improving folate, vitamin B12 or vitamin B6 status will decrease homocysteine 
concentrations among these older adults with mostly adequate B-vitamin status. Further 
work is needed to confirm the positive association of choline and homocysteine, and 
examine the potential influence of genetic polymorphisms. Lastly, dietary assessment 
and evaluation of major food group contributors of our select nutrients would provide 
further insight on nutrient adequacy, particularly given the assay limitations in 
evaluating vitamin B6 status.  
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7. Summary and Recommendations 
 
The United Nations has deemed population ageing as one of the most 
significant social transformations of the 21st century, with implications reaching almost 
all sectors of society (United Nations, 2019). Specific recommended actions to enable 
supportive environments to ensure health and well-being into old age have been made 
by a number of organisations (United Nations, 2019; World Health Organisation, 
2020). Likewise, in New Zealand, the Healthy Ageing Strategy and Better Later Life- 
He Oranga Kaumatua 2019 to 2034 have been developed, including the importance of 
nutrition in older adults (Ministry of Health, 2018; Ministry of Social Development, 
2019). 
 In the present study, B-vitamin status was mostly adequate however, the 
prevalence of hyperhomocysteinemia was high. These results were somewhat 
concerning given the finding of an inverse relationship of homocysteine with folate and 
vitamin B12. It does question whether increasing the folate and vitamin B12 status of 
our participants would be beneficial to lowering homocysteine – and thus, further 
questions whether the cut-offs applied to define adequate B-vitamin status are valid. 
Indeed, one of the biggest challenges in our study was the lack of consensus on which 
cut-off to use for each biomarker. Moreover, caution has been warranted regarding the 
extrapolation of cut-offs developed for one age group, typically healthy adults, to older 
adults, particularly given the known age-related physiological changes (Allen et al., 
2018). A recent expert review of nutritional biomarkers has detailed a number of issues 
when considering cut-offs including the need to better distinguish the physiological 
changes of ageing from the pathological changes, and the role and interference of 
medications when measuring biomarkers (Allen et al., 2018). The challenges raised in 
the present study to compare results across studies lend support to develop and 
harmonise cut-offs for the older and ageing population.   
The present study also revealed a somewhat concerning proportion of the 
sample population with high circulating levels of folate and vitamin B12 likely due in 
part to supplement use. Specifically, 82% of folate supplement users and 57% of 
vitamin B12 users were above the reference range. Similar to the aforementioned 
importance of developing cut-offs to establish the presence or absence of a health-
related condition, the development of an upper reference limit where appropriate, may 
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be of equal importance. Herein we used the upper reference limit of folate from the 
NHANES which was arbitrarily selected to reflect the upper limit of the assay used 
(Pfeiffer et al., 2005). The potential adverse effects of excess folate with or without a 
vitamin B12 deficiency is unknown. However, a better understanding of nutrient 
requirements and safe upper intake levels is needed. Efforts in this area are particularly 
important given the ongoing debate of mandatory folic acid fortification of the New 
Zealand food supply. Studies from NHANES data have shown that the geometric mean 
serum folate concentrations post-fortification were 2.5 times pre-fortification 
concentrations in the US (Pfeiffer et al., 2012). Furthermore, an Australian study that 
compared folate concentrations in two elderly cohorts pre-versus post-mandatory 
fortification folate concentrations, saw a significant increase in blood folate post-
mandatory fortification (serum folate 28.0 vs 23.9 nmol/L, p= 0.008 and RBC folate 
1243 vs 1066 nmol/L, p= 0.0005) and a decline of homocysteine concentrations (10.6 
vs 14.5 mol/L) (Beckett et al., 2017). In New Zealand folic acid fortification of certain 
foods with folic acid has been permitted since 1996 and fortification of bread with folic 
acid is permitted since 2012, but fortification is still not mandatory. The Ministry for 
Primary Industries reported that, 432 New Zealand products were fortified in 2017 
compared to 321 in 2013 in New Zealand (Ministry of Primary Industries, 2018). The 
question remains if fortification with folic acid would become mandatory in New 
Zealand would it substantially increase folate status in the older adult? The results of 
our study will provide baseline folate values for the older adults in RACF which would 
allow monitoring of the impact of folic acid fortification should policy in NZ change. 
Vitamin B12 does not have a set tolerable upper level and no adverse effects have been 
identified with high levels of vitamin B12. 
Results of vitamin B6 in our study are questionable as the assay used was not 
done on thawed bloods. This might have resulted in overestimating the prevalence of 
vitamin B6 deficiency. Investigations into vitamin B6 status using a more appropriate 
assay such as PLP would be of value given the high prevalence of 
hyperhomocysteinemia. 
Lastly, given the rapidly growing ageing population, representative national 
data on the nutrient status, intake and diet quality of older people, including both 
community-dwelling and those living in residential care, are needed to ensure healthy 
ageing and overall quality of life.  The last national survey is now over a decade old. As 
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such, addressing various nutritional challenges in this age group through the promotion 
of healthy food choices, food fortification, supplementation and reformulation of the 
food supply remains difficult.   
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Appendix A. Rest home recruitment protocol 
 
The location of data collection sites will be determined by where students will reside during their 
research placements, while maintaining a geographical spread across New Zealand (Figure A 1). 

















Figure A 1: Research locations for NZNAPs 
 
Rest homes will be identified via national aged care websites and by utilising dietetic networks 
throughout the country. The aim is to ensure provider diversity (private vs trust vs national 
ownership) and of contracted dietetic involvement across all research sites. 
Bed state is required to be at least 25 beds at rest home level care to ensure the student can achieve 
their recruitment goal of 20 participants from each rest home. However, smaller rest-homes will be 
needed to ensure provider diversity is achieved. Where a smaller rest home is recruited, the second 
rest home for the student will have more than 30 beds to achieve full recruitment (n=40) for the 
student’s MDiet project.  
Rest homes managers will be telephoned by Sue MacDonell, PhD investigator, who will describe 
the research study and outline the commitment required from staff at each rest home. Rest home 
Key: 
= semester 1 site 
= semester 2 site 
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managers that express interest in participating in the study will receive a follow up email with 
written information for their consideration. Rest-homes that agree to participate will be asked to 
sign and submit a registration of intent to participate, (Appendix B).
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Appendix B. Rest home registration of intent form 
 
Nutritional assessment of older New Zealand adults in residential care homes 
 
INITIAL REGISTSTRATION OF INTEREST 
FOR RESTHOMES 
 
I have read the Information Sheet concerning this project and understand what it is involved. All 
questions have been answered to my satisfaction. I understand that I am free to request further 
information at any stage. 
I know that:- 
1. Participation in the project is entirely voluntary; 
2. I am able to withdraw this rest-home from the project at any time without any disadvantage; 
3. Individual patient consent will be gained before residents can be included in the study; 
4.  Information collected on the patients from medical records, questionnaires, etc. will be entered 
into a password protected database and securely stored in such a way that only the researchers 
will be able to gain access to it. A unique ID will be assigned to each participant and all data will 
be identified by these unique codes. Information linking the IDs to the names of individuals will 
be securely stored in a locked filing cabinet in the principal investigators office. Every attempt will 
be made to preserve participant anonymity and all the data and results of the study will be 
published as a group. 
I agree to the rest-home named below taking part in this project pending full ethical approval being 
granted. 
 
.............................................................................    ............................... 
       (Signature of representative)       (Date) 
  
.............................................................................    
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Appendix C. Poster for recruitment 
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Appendix D. Participant Information Newsletter 
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Appendix E. Participant Information Sheet 
 
RHFORM02 Reference Number H13/118 
23 December 2013 
 
 
Nutritional assessment of older New Zealand adults in 
residential care homes 
 
INFORMATION SHEET FOR PARTICIPANTS 
 
Thank you for showing an interest in this project.  Please read this information 
sheet carefully before deciding whether or not to participate.  Take time to 
consider and, if you wish, talk with relatives or friends, before deciding 
whether to participate. 
 
If you decide to participate we thank you.  If you decide not to take part, there 




Poor nutrition in older adults is a major cause of ill health and reduced quality 
of life. Undernourished elderly have more frequent and longer hospital visits 
and higher risk of progressing to nursing home care. Studies across Australia, 
Europe and UK show that poor nutrient intake is common in rest homes, 
affecting 35%−85% of residents. However, there is little information on the 
nutritional status of residents in rest homes in NZ.  
 
Rest home residents have a high risk of poor nutrient intakes, because they 
have small appetites and may be unable to consume enough food to meet 
their nutritional needs. It is likely that many residents will benefit from 
strategies that improve the nutrient content of existing diets without the need 
for increasing food intake (e.g. supplementing meals with appropriate 
nutrients). However, in order to develop strategies to improve nutrient 
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intakes, information on dietary patterns, nutritional status, lifestyle and health 
of rest-home residents in NZ are needed. This is to ensure any interventions 
developed are safe, culturally acceptable and appropriate for the requirements 
of older New Zealanders. 
  
 
What is the aim of the project? 
The aim of this project is to collect information on the dietary intakes and 
nutritional status of New Zealanders residing in aged-care rest homes, to 
inform the development of safe and appropriate strategies to improve the 
health of these residents.  
We will examine dietary intakes and blood levels of iron; selenium; zinc; 
vitamins D, B12, B6 and folate. We will also examine levels of iodine and 
sodium (salt) in urine. These nutrients are known to be low in the diets of 
independent-living older New Zealanders, and low intakes are associated with 
ill health and disability. We will determine the prevalence of nutrition-related 
health conditions (e.g. anaemia, frailty, poor oral health), and investigate 
health and lifestyle patterns that may lead to nutrient deficiencies.   
 
Who is funding this project? 
The Department of Human Nutrition, University of Otago, is providing funding 
for this study.  
What type of participants are being sought? 
We are asking residents of rest homes in New Zealand to take part. People 
who are aged 70 years or older and who have lived in a rest home for ≥12 
weeks are eligible to participate.  
What will participants be asked to do? 
Should you agree to take part in this project, you will be asked to allow a 
trained Masters of Dietetics student to visit with you for three days to collect 
the following information: 
• A general health questionnaire pertaining to information on your age, 
ethnicity, education, medical and dental history, physical activity levels, 
cognitive function, wellbeing, vitamin supplement use, alcohol 
consumption and smoking history. Some of this information will be 
gathered from medical records held at the rest home. You do not have to 
answer all the questions and can stop at any time. 
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• Measure your weight, height, the length of your upper arm and lower, 
waist and lower leg circumference.  
 
• Collect a blood sample (22 ml – about 4 teaspoons) from you. An 
experienced registered nurse will take a sample of blood from you. 
Occasionally, a small bruise may appear where the blood sample was 
taken, but this normally disappears within a few days. Blood samples will 
be analysed for iron, zinc, selenium, vitamin D and other B-vitamins status 
including vitamin B12, B6, choline, betaine, riboflavin and folate.  
 
• Collect a urine sample from you. We will provide you with a small 
container and urine collection vessel, to collect a small urine sample. This 
will be analysed for iodine and sodium status. 
 
• The dietetic student will carry out a 3-day weighed food record for you. 
The student will weigh and record all of the food and drink you consume 
on two weekend days and one weekend day. They will also record any 
dietary supplements you consume during these 3 days. 
 
• You will be asked to complete a short physical function test. For this test, 
the student will time you while you walk of approximately 5 metres (15 
feet).  
 
You will be provided with your laboratory results once they become available 
at the end of the study. 
Is there any risk of discomfort or harm from participation? 
There is a slight increased risk of falling during the timed walk test. The dietetic 
student is trained to assist you to reduce the risk of falling. In addition, a rest 
home staff member will be available to ensure you do not fall. 
 
What data or information will be collected and what use will be made of it? 
The information collected on your general health, cognition, functional status 
and wellbeing will be used to understand and characterise some of the 
relationships between diet and nutrient status. Only the study investigators 
will have access to your personal information and all data collected for the 
project will be stored separately labelled with an ID number. You may request 
at any time to have your data returned to you or destroyed. 
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The data collected will be securely stored in such a way that only those 
mentioned below will be able to gain access to it. Data obtained as a result of 
the research will be retained for at least 10 years in secure storage. Any 
personal information held on the participants may be destroyed at the 
completion of the research even though the data derived from the research 
will, in most cases, be kept for much longer or possibly indefinitely. 
 
Blood and urine samples will be stored in locked refrigerators at the 
Department of Human Nutrition, University of Otago. All remaining samples 
will be disposed at the end of the laboratory analyses. Biological samples will 
be disposed with a Karakia if requested.   
 
The results of the project may be published and will be available in the 
University of Otago Library (Dunedin, New Zealand) but every attempt will 
be made to preserve your anonymity. 
 
Can Participants Change their Mind and Withdraw from the Project? 
You may withdraw from participation in the project at any time and 
without any disadvantage to yourself of any kind. 
What if Participants have any Questions? 
If you have any questions about our project, either now or in the future, please 
feel free to contact either: 
 
Mrs Sue MacDonell and/or Dr Jody Miller 
Clinical Dietitian / PhD student Principal Investigator 
Department of Human Nutrition Department of Human Nutrition 
University Telephone Number:  University Telephone Number: 
   (03) 479 7524     (03) 479 5689 
Email Address   Email Address 
sue.macdonell@otago.ac.nz  jody.miller@otago.ac.nz 
  
 
This study has been approved by the University of Otago Human Ethics 
Committee. If you have any concerns about the ethical conduct of the research 
you may contact the Committee through the Human Ethics Committee 
Administrator (ph 03 479 8256). Any issues you raise will be treated in 





Appendix F. Participant consent from 
 
RH FORM03 Reference Number H13/118 
  23 December 2013 
 
 
Nutritional assessment of older New Zealand adults in 
residential care homes 
 
CONSENT FORM FOR PARTICIPANTS 
 
I have read the Information Sheet concerning this project and 
understand what it is about.  All my questions have been answered to 
my satisfaction.  I understand that I am free to request further 
information at any stage. 
 
I know that: 
 
1. My participation in the project is entirely voluntary; 
 
2. I am free to withdraw from the project at any time without any 
disadvantage; 
 
3. Personal identifying information will be destroyed at the conclusion 
of the project but any raw data on which the results of the project 
depend will be retained in secure storage for at least ten years; 
 
4.  I know that as a participant I will complete some questionnaires, 
with the help of the research dietetic student, and undergo 
measurements of cognition and physical function.  
 
5. I understand that the research dietetic student will access my 
medical records held at the rest home, to collect information on my 






6. I understand the nature and size of the risks of discomfort or harm 
which are explained in the information sheet. 
 
7. The results of the project may be published and will be available in 
the University of Otago Library (Dunedin, New Zealand) but every 
attempt will be made to preserve my anonymity.  
 
8. At the end of the study, I consent to any remaining blood or urine 
samples being disposed of using:  
 
   Standard disposal methods, OR; 
 
   Disposed with appropriate karakia 
 




       (Signature of participant)    (Date) 
 
 
This study has been approved by the University of Otago Human 
Ethics Committee. If you have any concerns about the ethical 
conduct of the research you may contact the Committee through the 
Human Ethics Committee Administrator (ph 03 479 8256). Any issues 
you raise will be treated in confidence and investigated and you will 












 Reference Number H13/118 
 23 December 2013 
 
 
Nutritional assessment of older New Zealand adults in 
residential care homes 
 
CONSENT FORM FOR LEGAL GUARDIANS 
   
The person being asked to be in this research study may not be able to give consent to be in 
this study.  You are therefore being asked to give permission for this person to be in the study 
as his/her decision maker. In doing so, the following is understood: 
 
I have read the Information Sheet concerning this project and understand what it is about.  All 
my questions have been answered to my satisfaction and it is understand that both  
 
________________________________________  and myself are free to request further  
   (Participant’s name) 
 information at any stage. 
 
I know that: 
 
1. Participation in the project is entirely voluntary; 
 
2. The participant is free to withdraw from the project at any time without any disadvantage; 
 
3. Personal identifying information will be destroyed at the conclusion of the project but any 
raw data on which the results of the project depend will be retained in secure storage for at 
least ten years; 
 
4.  Either myself or the participant I will complete some questionnaires, with the help of the 
research dietetic student, and the participant will undergo measurements of cognition and 
physical function.  
 
5. I understand that the research dietetic student will access the participant’s medical records 
held at the rest home, to collect information on their general health and use of medications 
and dietary supplements. 
 
6. I understand the nature and size of the risks of discomfort or harm which are explained in 






7. The results of the project may be published and will be available in the University of Otago 
Library (Dunedin, New Zealand) but every attempt will be made to preserve the 
participant’s anonymity.   
 
 
8. At the end of the study, I consent to any remaining blood or urine samples being disposed 
of using:  
 
   Standard disposal methods, OR; 
 




My signature indicates that I agree for _______________________________ to take part in 
this project.      (Participant’s name) 
 
 
.............................................................................   ............................... 
       (Signature of legal guardian)      (Date) 
 
This study has been approved by the University of Otago Human Ethics Committee. If you have any concerns 
about the ethical conduct of the research you may contact the Committee through the Human Ethics 
Committee Administrator (ph 03 479 8256). Any issues you raise will be treated in confidence and investigated 


































Appendix J. Demographic and Medical Questionnaire 
 
RH FORM05 Demographic and medical questionnaire 
 
WRITE PARTICIPANT’S ID NUMBER HERE: 
 
INTERVIEWER INSTRUCTIONS 
▪ Please gather as much information for this questionnaire from medical records 
or rest-home staff.   
▪ Only when information is not available from these sources, or if information 
needs clarification, should you ask the participant directly. 
▪ Indicate the correct answer with X 
▪ Please indicate the source of the information from by circling the appropriate 
abbreviation next to the question: 
o MR / staff / participant / Other___(specify, e.g. family) 
(MR = medical records) 
 
 
1. When was the participant admitted into the rest home? 
 
             /             /              (dd/mm/yy)      MR / staff / participant/ Other______ 
 
If this information is not available please give an estimate of the months/years 












3.  Date of birth 
 
             /             /              (dd/mm/yy)      MR / staff / participant/ Other______ 
 
 






4.  Which country was the participant born in?  
 
 ☐ New Zealand (Go to question 5) 
 ☐ Australia 
 ☐ England 
 ☐ Scotland 
 ☐ China (People’s Republic of) 
 ☐ South Africa 
 ☐ Samoa 
 ☐ Cook Islands 
 ☐ other Please specify      
 ☐ Information not available (Go to question 5) 
 




 If the participant was NOT born in New Zealand, in what year did she/he 
first arrive?  
 





5.  Which ethnic group does the participant belong to?  
  
Please tick the box or boxes that apply.  
 
 ☐ New Zealand European  
 ☐ Māori  
 ☐ Samoan 
 ☐ Cook Island Maori  
 ☐ Tongan  
 ☐ Niuean 
 ☐ Chinese 
 ☐ Indian 
☐ Other such as Dutch, Japanese, Tokelauan Please specify    
 ☐ Information not available  
 









6.  What is the participant’s marital status?  
 ☐ married / civil union, (Go to question 7) 
 ☐ de facto (living with a partner), (Go to question 7) 
☐ in a relationship, but NOT living with a partner, (Go to question 7) 
☐ separated / divorced 
 ☐ widowed 
 ☐ single, (Go to question 7) 
 ☐ Information not available, (Go to question 7) 
MR / staff / participant/ Other_________ 
 
 
 How long has the participant been widowed/separated/divorced? 
 





7.  Does the participant have family that come to visit? 
 
 ☐ yes                                                   MR / staff / participant/ Other_________
  




 How often does the participant get visits from family? 
 
 _______________________               MR / staff / participant/ Other_________ 
 
 
8.  What is the highest education qualification the participant has 
completed?  
  
 ☐ left before high school (before third form) 
 ☐ some high school (third form to before the end of sixth form) 
 ☐ completed high school to Sixth Form Certificate 
 ☐ completed high school to University Bursary 
 ☐ further training (e.g. apprenticeship) 
 ☐ tertiary (diploma or degree) 
 ☐ postgraduate qualification (Master’s or PhD) 
 ☐ other Please specify         
 ☐ Information not available 
 








9.  What was the occupation of the participant prior to retirement? 
 Indicate here if information not available  
   
 _____________________________________________________________ 
 




10.  In the last THREE MONTHS, has food intake declined due to loss of 
appetite, digestive problems, chewing or swallowing difficulties?  
 
 ☐ No  
 ☐ Yes , moderate decrease in food intake 
 ☐ Yes , severe decrease in food intake 
MR / staff / participant/ Other_________ 
 
 
11. Has the participant been eating poorly because of a decreased appetite? 
 
 ☐  yes   
☐  no   




12.  In the LAST YEAR, has the participant lost more than 4.5 kg (10 
pounds)?  
 
 ☐ No, (Go to question 13)                   MR / staff / participant/ Other_________
  
 ☐ Yes  
 
 
 Before the participant lost weight, what was his/her body weight?  
 




 If the patient has lost weight, ask if they were trying to lose weight. (i.e. 
was the weight loss intentional?) 
 
 ☐  weight loss was intentional             MR / staff / participant/ Other_________ 
  








13. Mobility: Is the participant  
 ☐  bed or chair bound   
☐  able to get out of bed / chair but does not go out  
☐  goes out  
 




 14. Has the participant suffered psychological stress or acute disease in the 
past THREE MONTHS? 
 
 ☐  yes                                                  MR / staff / participant/ 
Other_________ 
 





15.  Does the participant suffer from any of the following neuropsychological 
problems ? 
 
 ☐  severe dementia or depression      MR / staff / participant/ Other_________ 
☐  mild dementia  




16.  Is the participant acutely unwell and there has been, or is likely to be no 
nutritional intake for > 5 days 
 











Appendix K. Handgrip strength test 
Handgrip strength will be measured using a Hand Dynamometer. The test is to be performed on 
each hand. 
1. Sit the participant comfortably in a standard chair with legs, back support and fixed arms. 
Use the same chair for every measurement. 
2.  Ask them to rest their forearms on the arms of the chair with their wrist just over the end of 
the arm of the chair— wrist in a neutral position, thumb facing upwards.  
3.  Demonstrate how to use the Jamar handgrip dynamometer to show that gripping very 
tightly registers the best score.  
4.  Start with the right hand.  
Position the hand so that the thumb is round one side of the handle and the four fingers are 
around the other side. The instrument should feel comfortable in the hand. Alter the 
position of the handle if necessary.  
5. The observer should rest the base of the dynamometer on the palm of their hand as the 
subject holds the dynamometer. The aim of this is to support the weight of the 
dynamometer (to negate the effect of gravity on peak strength), but care should be taken 
not to restrict its movement.  
6. Encourage the participant to squeeze as long and as tightly as possible or until the needle 
stops rising. Once the needle stops rising the participant can be instructed to stop squeezing 
7. Read handgrip strength in kilograms from the outside dial and record the result to the 
nearest 1 kg on the data entry form. 
8. Repeat measurement in the left hand.  
9. Do two further measurements for each hand alternating sides to give three readings in total 
for each side. 
10. The best of the six handgrip strength measurements is used in statistical analyses so as to 
encourage the subjects to get as high a score as possible.  
11. Also record hand dominance, i.e. right, left or ambidextrous (people who can genuinely 
write with both hands).  
 
Equipment: Model J00105 JAMAR Hydraulic Hand Dynamometer. 
 
Cutoff for handgrip strength (Kg) criterion for frailty (Fried et al) 
Men   Women 
BMI < 24 frail if <29 kg BMI < 23 frail if <17 kg 
BMI 24.1–26  frail if <30 kg  BMI 23.1–26 frail if <17.3 kg 
BMI 26.1–28  frail if <30 kg  BMI 26.1–29 frail if <18 







Appendix L. Anthropometric measurements 
Safety consideration: There is a risk of falling when participants transfer to weighing scales and step 
on and off the stadiometer. You should check with the rest-home staff as to whether they consider 
the participant is safe to mobilise without assistance. 
 
A rest-home care giver will be in attendance during measurements to ensure participant safety, so 
you will need to organise a time for the test that suits both the participant and care giver. 
 
Gain verbal consent from the participant for each measurement and explain fully what you will do to 
obtain them. Before beginning, gain consent from the participant to use non-permanent pen for 
marking anatomical land marks. 
NB: anthropometry tapes have a blank lead before measurement markings start - consider this 




1. Ask the participant to remove any heavy clothing (such as jackets, heavy tops, boots etc). As 
the participant would have just had their height measurement done, they should not be 
wearing shoes. 
2. Turn on the scales, ensure they are switched on to metric (kg). 
3. Ask the participant to step on to the scales explaining and cautioning them that they need to 
step up onto the scales. 
4. Wait for the scales to read or come to a stable number. 
5. Record the participant’s weight to the nearest 0.1 kg. 










10. Ask the participant to remove their 
shoes, as well as any hair ornaments or 
buns/braids on the top of the head. 
 
11. Tell the participant to stand with their 
heels together and toes apart pointing 
outward at approximately a 60-degree 
angle. 
 
12. Make sure the back of the head, 
shoulder blades, buttocks, and heels of 
the participant are touching the 
backboard/stadiometer. 
 
13. Make sure the participant’s head is 
aligned in the Frankfort horizontal 
plane, where a horizontal line connects 
from the ear canal to the lower border 
of the orbit of the eye. 
 
14. Lower the headpiece to rest firmly on 
the top of the participant’s head and 
ask the participant to stand as tall as 
possible and take a deep breath. 
 
15. Record the result to the nearest 0.1 
cm. 
 
16. Repeat for a second measurement. 
 
17. If the second measurement is not 
within 0.5 cm, a third measurement 

















(accessed at: http://www.mna-elderly.com/mna_forms.html and http://www.rxkinetics.com/height_estimate.html 
on 20.11.2013)  
 
A. Ulna length: 
Ulna length is measured between the point of the elbow and the midpoint of the prominent bone of 
the wrist using an anthropometric tape. This value is then compared with a standardized height 
conversion chart. Participants should be dressed in light clothing with no wrist watch or other 
jewellery on the arm that is to be measured. 
Method: 
 
1. Measure between the point of the elbow and the midpoint of 
the prominent bone of the wrist (non-dominant side) 
2. Read and accurately record the measurement to the nearest 0.1 
cm.  





B. Calf Circumference: 
The subject should be standing with their weight evenly distributed on both feet. 
Method: 
1. Ask the patient to roll up the trouser leg to uncover the calf. 
2. Wrap the tape around the calf at the widest part and note the measurement. 
3. Take additional measurements above and below the point to ensure that the first measurement was the 
largest. 
4. An accurate measurement can only be obtained if the tape is at a right angle to the length of the calf. 
5. Read and accurately record the measurement to the nearest 0.1 cm.  
6. The measurement should be taken three times. Repeated measurements should agree within 0.5 cm. 
 
Measuring Calf Circumference in bed-bound persons 
1. Have the person being measured lie in a supine position with the left knee bent at 90° angle.  
2. Slip a loop of the tape measure around the left calf until largest diameter is located. 
3. Pull tape so it is just snug but not so tight that tissue is compressed.  
4. Read and accurately record measurement to the nearest 0.1 cm.  
5. The measurement should be taken three times. Repeated measurements should agree within 0.5 cm. 
  
 

















Appendix N. Geriatric Depression Score Short Form 
 
 
Figure A.3: Geriatric Depression Scale (Short Form). Highlighted answers are 







Appendix O. Blood sample collection-relevant to this thesis 
 
At the rest home: 
 
The student will arrange appointments with the registered nurse or the rest-homes usual 
phlebotomist for fasting blood sample collection. 
 
▪ When appointments are made, please email the date of collection, and ID numbers for each 
participant to Jody Miller (jody.miller@otago.ac.nz), who will liaise with Canterbury Health 
Laboratories to collect and process the samples.    
 
Blood Samples 
Tubes will be labelled with the participant’s study ID number, date and time of collection. 
  
Patients will be seated for at least 5 minutes prior to sampling. 
 
26 mL of blood will be drawn into: 
 
 6.0 mL K2EDTA Dark Blue Trace Metal Tube 
 6.0 mL Red Tube 
 6 mL K2EDTA Lavender Tube 
 4.0 mL Red Tube 
 4 mL K2EDTA Lavender Tube 
 
Samples will be kept on ice.  
 
 
At the clinic: 
 
Canterbury Health Laboratories (CHL) will measure haemoglobin and CBC. Then aliquots of whole 








CHL blood processing chart 
 
 
4.0mL K2EDTA Lavender 
Tube 
6.0mL K2EDTA Dark 
Blue Trace Metal Tube 
6.0mL Red Tube 
6.0mL K2EDTA 
Lavender Tube 
4.0 mL Red Tube 
1. 
Analysis:  
2.0 mL whole blood – 
CBC/Hb 
Spin 3000 rpm for 5 
minutes 
Spin 3000 rpm for 5 minutes 
Spin 3000 rpm for 5 
minutes 




2 x 0.1 mL whole blood into 
900 L 1% ascorbic - folate  
Aliquot plasma: 
0.500 mL – selenium 
0.500 mL – zinc 
0.500 mL – folate 
1.000 mL – MMA 
Aliquot serum: 
0.500 mL –  B12 
0.500 mL – ferritin 
0.500 mL –  sTfR 
0.600 mL – choline/betaine 
0.600 mL – one-carbon 
nutrients 
Aliquot plasma: 
0.500 mL –B6 
0.500 mL – IL-6 
0.500 mL – AGP 
0.500 mL –hs-CRP 
0.500 mL – blood lipids 
 
Aliquot serum: 
0.500 mL –25(OH)D 
2 x 1.000 mL – 1,25(OH)D 




Aliquot whole blood: 
2 x 0.400 mL – GPx 
1 x 0.500 mL –riboflavin 
(protect from light) 
    






RH SOP09 Laboratory tests 
 
Blood tests: 
1. High senstivitiy C-Reactive Protein (hs-CRP) (Measure of acute infection) 
2. Alpha-1-glycoprotein (AGP)   (Measure of chronic infection) 
3. IL-6      (Measure of inflammation) 
4. Vitamin B12 and B6 and Folate (whole blood and plasma) 
5. One carbon metabolism nutrients (including betaine, choline) 
 
Testing laboratories 
1. University of Otago, Department of Human Nutrition, New Zealand 
2. Canterbury Health Laboratories (for haemoglobin and CBC) 
 
Sample requirements   
1. Complete Blood Count 
Tube: Trace element free vial, 1.7 mL Volume: 100 µL plasma 
Stability: The analysis will be completed immediately.  
Analysis:  At Canterbury Health Laboratories, Christchurch (or local clinic) 
 
2. Whole Blood Folate 
 Tube: Trace element free vial, 1.7 mL Volume: 100 µL plasma 
 Stability: The 100 µL aliquot of whole blood, pipetted directly from the blood collection 
tube using a trace element free pipette tip, needs to be mixed with a 900 µL volume of a 
1% (w/v) ascorbic acid solution and then stored at -20°C in a 1.7 mL microcentrifuge tube. 
 The treated whole blood can be stored for 1 year at -20°C at Department of Human 
Nutrition, University of Otago. 
 Analysis:  At University of Otago, Department of Human Nutrition Lab 
 
4. CRP, AGP 
 Tube: Polyvial (250 µL)   Volume: 150 µL plasma  
 Stability: The blood sample must be spun down within 30-60 minutes and plasma 
separated into small plastic vials. Serum can be stored for 1 year at -20°C at Department 
of Human Nutrition, University of Otago.  
 Analysis:  At University of Otago, Department of Human Nutrition Lab 
   Sandwich ELISA technique 
 
6. Folate, Vitamin B12, Riboflavin, one-carbon nutrients 
 Tube: Trace element free vial (1.7 mL) Volume: all remaining plasma 
 Stability: The blood sample must be spun down within 30-60 minutes and plasma 
separated into small plastic vials. Serum can be stored for 1 year at -20°C at Department 
of Human Nutrition, University of Otago. 
 Analysis:  At University of Otago, Department of Human Nutrition Lab 
 
 
 
